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POPULAR SCIENCE SUMMARY OF THE THESIS 
Signs and symptoms of psoriasis at onset can predict the course of the disease and it may be 
possible to modify the risk of developing severe psoriasis with early systemic intervention. 
This is important because severe psoriasis is associated with impaired quality of life, 
increased risk of death, high health care costs, and suboptimal treatment outcomes.  
Study 1 in this thesis followed 721 patients from onset of psoriasis and ten years thereafter. 
The study found that patients with plaque phenotype, more than mild disease activity, and 
scalp lesions at onset had a probability of 52% to develop severe psoriasis compared to 11% 
in patients with mild disease activity at onset (p<0.001). Furthermore, patients with pain at 
sites where tendons attach to bone were almost five times more likely to develop psoriatic 
arthritis, a debilitating joint disease, than patients without joint pain at onset (59% vs 12%, 
p<0.001). Among all patients treated with systemics for psoriasis, patients who were treated 
within one year of disease onset had lower risk of having severe psoriasis after ten years 
compared with patients who were treated thereafter (38% vs 65%, p=0.044). 
Study 2 in this thesis identified 39,074 patients with psoriasis and 154,775 control individuals 
without psoriasis in regional Swedish health data registers and followed them for up to nine 
years. The study found that patients with mild and severe psoriasis died on average 0.8, and 
2.6 years younger than controls without psoriasis. The cause of death contributing most to the 
excess mortality was cardiovascular disease, accounting for 48% of the excess mortality in 
patients with mild disease and 33% in patients with severe disease. Analyzing data from a 
subset of these patients alive in 2010, Study 3 estimated the economic impact of psoriasis. 
The economic impact of psoriasis generally increased with disease severity. However, the 
study also found that effective treatment might reduce costs. Study 4 also used a subset of 
patients from the study on mortality and explored how patients with psoriasis were treated. 
Irrespective of whether patients were treated with topicals, systemics, or biologics a majority 
of patients discontinued, switched, or received add-on therapy within one year of treatment 
start. Furthermore, within one year of having discontinued treatment, 49% of patients on 
topicals, 61% of patients on systemics, and 80% on patients on biologics, restarted the same 
or another treatment. 
Study 5 in this thesis analyzed data on 727 treatment episodes with adalimumab, etanercept, 
and methotrexate in 542 patients. The study found that adalimumab might be a good choice 
as first line systemic treatment for psoriasis: Patients treated with adalimumab had better drug 
survival, lower disease activity, and better quality of life than patients treated with 
methotrexate, the most frequently prescribed first line systemic treatment in psoriasis. 
Nevertheless, the results indicate that even with adalimumab, mean PASI during maintenance 
treatment was higher than some recent treatment goals and patients still had impaired quality 
of life.  
Psoriasis is a chronic inflammatory skin disease that affects both body and psyche. It is 
associated with comorbidities including heart attack, stroke, and cancer. In recent years, 
advances in medicine have improved treatment of psoriasis. However, much is still unknown 
about the clinical course of the disease, its impact on mortality, economic burden, and 
treatment effectiveness in clinical practice. This thesis aims to address these knowledge gaps 
with the ultimate goal to help improving the care of patients with psoriasis.  
Overall findings from these studies reinforce the notion that plaque psoriasis is a chronic 
disease associated with substantial burden both from economic and clinical perspectives. 
Identification of subgroups of patients with adverse prognosis may contribute to better and 
more cost-effective management of the disease. The finding that early systemic intervention 
may affect the disease course may affect the treatment paradigm in psoriasis, but needs to be 





Better understanding of long-term prognosis, clinical course, comorbidities, economic 
burden, and treatment of psoriasis, can improve care of patients with the disease and may 
inform decisions on resource allocation, benefitting not only patients but also the society in 
general. 
The Stockholm Psoriasis Cohort (SPC), Study 1, was initiated to describe the clinical course 
or psoriasis. The SPC enrolled 721 patients with onset of psoriasis within the last twelve 
months. 542 (75%) patients had plaque psoriasis and 174 (24%) had guttate psoriasis. 
Patients were followed in medical records and registers, and among the 686 participants alive 
after ten years, 546 (80%) responded to a questionnaire and 509 (74%) were also examined 
clinically. Plaque psoriasis was strikingly persistent. Forty one percent of the patients with 
severe disease at onset had severe disease at ten years compared with 9% of participants with 
mild or moderate disease at onset (Relative Risk [RR]=4.3; p<0.001). Guttate onset was 
associated with a favorable disease course: After ten years, 56/116 (48%) of patients were in 
remission without treatment and only 1/94 patients with mild or moderate guttate onset had 
severe psoriasis at ten years. Recursive partitioning analysis identified groups with distinctive 
risks for severe skin disease and Psoriatic Arthritis (PsA): The cumulative incidence of severe 
disease in participants with plaque phenotype, at least moderate disease, and scalp psoriasis at 
onset was 52% (95% Confidence Interval [CI]: 41% to 64%), compared to 11% (95% CI: 8% 
to 14%) in patients with mild disease at onset. Forty-eight of 82 patients (59%) with 
peripheral enthesitis at onset had PsA after ten years compared to 37/304 (12%) without 
arthralgia at onset (p<0.001). Systemic treatment at or before enrolment was associated with 
reduced risk for severe disease at ten years compared to systemic initiation later (Odds Ratio: 
0.24; 95% CI: 0.06 to 0.90). Overall, this study indicates that the course of psoriasis can be 
predicted with good discriminatory power and that it may be modified by early effective 
intervention. The latter finding should be confirmed in randomized controlled clinical trials. 
The second study estimated all-cause and cause-specific mortality in 34,355 patients with 
mild psoriasis and 4,719 patients with severe psoriasis compared to 154,775 age- sex- and 
residency matched controls. The study found that patients with mild and severe psoriasis had 
excess all-cause mortality: Hazard ratio (HR) 1.15 (95% CI: 1.10 to 1.21) for patients with 
mild psoriasis, and HR 1.56 (95% CI: 1.36 to 1.79) for patients with severe psoriasis. 
Cardiovascular disease accounted for the largest proportion of excess mortality (48% in mild 
psoriasis and 33% in severe psoriasis). For patients with mild and severe psoriasis, the causes 
of death with the highest excess risks were kidney disease (HR: 2.20; 95% CI: 1.36 to 3.56), 
and liver disease (HR: 4.26; 95% CI: 1.87 to 9.73), respectively. The findings suggest that it 
may be valuable to screen patients with psoriasis for cardiovascular, kidney, and liver disease.  
Economic burden of psoriasis in 2010 and potential cost offsets with biologic treatment were 
estimated in Study 3, using data on 31,043 patients with psoriasis and 111,645 sex-, age- and 
residency-matched controls. Patients had higher direct and indirect costs compared to 
controls after adjusting for the Charlson Comorbidity Index (CCI): USD 3,555 versus USD 
2,190 (p < 0.001) for direct costs and USD 9,898 versus USD 6,579 (p < 0.001) for indirect 
costs. Both mean direct and mean indirect costs generally increased with disease severity 
inferred by most potent treatment received, albeit the increase was not monotonic. 
Disregarding the costs of biologics, initiation of biologic treatment was estimated to generate 
one-year direct and indirect cost offsets from USD 1,135 (95% CI: 328 to 2,050) to USD 
4,422 (95% CI: 2,771 to 6,552), and USD 774 (95% CI: -535 to 2,019) to USD 1,875 (95% 
CI: 188 to 3,650), respectively. Collectively, these findings show that psoriasis is associated 
with substantial direct and indirect costs, which may be modifiable with effective treatment. 
Study 4 described treatment patterns in 19,103 patients with psoriasis and estimated the one-
year cumulative incidences of treatment events (discontinuation, switch, or augmentation) 
with topicals, systemics, and biologics at 93%, 72%, and 75%, respectively. Within one year 
of having discontinued treatment, the cumulative incidences of starting a new treatment was 
49% for topicals, 61% for systemics, and 80% for biologics. These findings highlight the 
unmet needs across the disease spectrum and underscore the chronicity of the disease.  
Study 5 estimated real-world effectiveness of adalimumab and etanercept compared to 
methotrexate. After adjusting for confounders, adalimumab had better drug survival (HR: 
0.67; 95% CI: 0.51 to 0.88), lower mean predicted PASI (-2.0; 95% CI: -2.6 to -1.5) and 
DLQI (-0.9; 95% CI: -1.5 to -0.3) during maintenance treatment than methotrexate. The 
results for the comparison between etanercept and methotrexate were more mixed. These 
findings support adalimumab as first line systemic treatment for psoriasis, but further data, 
especially on safety and costs, are needed.  
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1.1.1 Clinical manifestations and diagnosis 
Psoriasis is an immune-mediated skin disease with a predisposing genetic component (1). 
The disease exhibits substantial variability in morphology, distribution, and severity (2). 
Lesions may occur at any site, but  most frequently affect the scalp, elbows, knees, forearms, 
shins and the trunk (1). The disease course is variable (3). It may be chronic with stable 
lesions or may fluctuate between periods of substantial disease activity and remissions (3). 
Episodes of increased disease activity may be associated with growth of existing lesions or 
appearance of new lesions (4). 
Psoriasis is primarily a clinical diagnosis ascertained by a combination of features, 
morphology and configuration of skin lesions (5). The reference standard for diagnosing the 
disease is a clinical diagnosis made by a dermatologist (5). The agreement on diagnosis of 
both typical and atypical psoriasis among dermatologists have been reported at 97% (6), 
indicating high face validity. Nevertheless, other skin disorders may resemble psoriasis and if 
the diagnosis is uncertain, histopathological analysis of skin biopsies can aid differential 
diagnosis (5). 
Several disease classification systems exist and in 2006, the International Psoriasis Council 
(IPC) published a simplified classification comprising four main phenotypes based on 
morphology: plaque psoriasis, guttate psoriasis, pustular psoriasis, and erythrodermic 
psoriasis. (7) 
Plaque psoriasis (Figure 1A) is the most common form, affecting approximately 90% of 
patients with psoriasis. In plaque psoriasis, lesions are generally clearly demarcated red 
plaques covered by silvery scales. In terms of distribution, plaques may range from few and 
limited in size to large and widespread, covering a substantial area of the body. The IPC 
further divided plaque psoriasis into five phenotypes based on lesion morphology and 
location: flexural, seborrheic, scalp, palm and sole, and follicular psoriasis. (7) 
Guttate psoriasis (Figure 1B) is characterized by red droplets which may be widespread. 
Lesions are often located on the trunk, but may appear all over the body. Guttate psoriasis is 
most common in children, adolescents, and young adults. It is often preceded by a 
streptococcal infection. Lesions may resolve over three months but may also develop into 
plaque psoriasis. Guttate lesions may also present in patients with plaque phenotype. (7) 
Pustular psoriasis (Figure 1C) presents as blisters of non-infectious pus. Blisters may be 
localized affecting, for example, palms and soles or generalized with dark red patches, 
congregating into large areas of pus. Pustular psoriasis may occur in patients with plaque 
phenotype but may also develop in individuals without a history of psoriasis. (7) 
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Erythrodermic psoriasis is a serious condition (Figure 1D) characterized by extensive 
(covering ninety percent or more of the skin) erythema with a high degree of inflammation 
and may result in shedding of the skin. The disease may be preceded by plaque psoriasis but 




Figure 1 Main psoriasis phenotypes as defined by the International Psoriasis Council. Panel A shows plaque 
psoriasis. Panel B shows guttate psoriasis. Panel C shows pustular psoriasis. Panel D shows erythrodermic psoriasis. 
Photographs reproduced with permission from the Karolinska University Hospital.  
No common pathogenic mechanism for the disease has been established and the different 
phenotypes are considered variants of the same disease from a morphological point of view. 
The reason is fourfold: A red and scaly appearance is the most common feature in all 
manifestations and sponge like pustules is a frequent characteristic; (ii) different 
manifestations may be contemporaneous; (iii) different manifestations may occur 
sequentially; and (iv) members of a single family may exhibit different phenotypes. (8)  
The manifestations of psoriasis may differ systematically between ethnicities. A survey of 
American dermatologists indicated that African-American patients had less erythema but 
more dyspigmentation than white patients (9). Furthermore, small plaques are found be more 
prevalent in Asian than European patients (10).  
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Psoriatic arthritis (PsA) is an inflammatory joint disease common in individuals with 
psoriasis and typically occurs after the onset of skin disease. The features of PsA are 
clinically diverse and no laboratory test definitively identifies the disease. Inflammation can 
involve distal interphalangeal joints, be symmetric or asymmetric, involve only single large 
joints such as the knee, or be axial, affecting the spine. Symptoms of the disease include pain, 
stiffness, impaired functioning, and progressive degeneration of the affected joints. In 
addition, PsA is characterized by painful inflammation in the soft tissues surrounding the 
joints, enthesitis. The most severe and rare phenotype is arthritis mutilans with destructive 
inflammation typically in fingers and toes. (11) 
The course of PsA is heterogeneous, but is frequently progressive and spontaneous remission 
is rare (11). The disease is heavily linked to psoriasis and psoriasis is a major factor in the 
diagnosis of PsA (12). Nevertheless, reflecting differences in genetics, clinical course, and 
impact of treatment; it is debated whether PsA should be defined as a manifestation of 
psoriasis or a separate disease and therefore a comorbidity (12). 
1.1.2 Nosology 
Given the absence of biomarkers and formal diagnostic criteria, presence or absence of 
psoriasis is arguably a matter of perspective. For example, some researchers have discussed 
the notion of a preclinical phase of psoriasis (3, 13). In such a perspective, a patient has 
psoriasis before it has manifested clinically. On the other hand, instances of spontaneous 
remissions lasting decades have also been reported (14). A key notion may be whether 
predisposition to clinical manifestations are considered a disease. Such considerations may 
develop over time (15). For example, osteoporosis, a condition that confers increased risk of 
fragility fracture, was officially recognized by the WHO as a disease in 2004 and thereby 
took a large step from being viewed as a natural part of ageing to a recognized pathology 
(15). For psoriasis, there appears to be no formal agreement on the matter, potentially because 
risk factors and the clinical course of the disease are insufficiently described, prohibiting 
development of consensus. 
1.1.3 Pathogenesis 
Psoriatic lesions result from abnormal differentiation and growth of keratinocytes. The 
pathogenesis for this process is incompletely understood but reflects upregulation of the 
cellular immune system, dendritic cells, T cells, and immune-related chemokines and 
cytokines. The disease has a strong genetic component. (16) 
The causative model for psoriasis includes genetic and environmental factors and their 
interaction; with genetic factors explaining 70% of disease susceptibility (17). Several 
candidate genes have been identified including the human leukocyte antigen (HLA)-C locus 
on chromosome six (18). A number of environmental triggers for psoriasis have been 
reported including smoking, excessive alcohol consumptions, obesity, and stressful life 
events (19). Infections may also play a role and streptococcal infection often precedes onset 
of guttate psoriasis (20).  
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Historically, other, now discarded, theories on the pathogenesis of psoriasis existed. For 
example, psoriasis was hypothesized to be infectious, and a French researcher reportedly 
developed lesions after scaring the skin over his deltoid and rubbing in psoriatic scales into 
the scars: Plaques appeared at the elbows two days after the inoculation and lesions were 
well-marked after two weeks (21). On the basis of the high serum cholesterol, it was also 
hypothesized that psoriatic lesions resulted from lipid accumulation in the skin (22). Other 
hypotheses included that the disease originated from the joints, that it was neuropathic in 
nature, and that psoriasis was a parasitic disease – a notion that explained clustering of the 
disease in families, and which was popular in the early 20th century (23). James Nevins Hyde, 
who was among the first to recognize the association between exposure to sunlight and skin 
cancer, hypothesized that psoriasis was the result of the inverse relationship, i.e. that 
susceptible individuals developed psoriasis due to lack of light exposure (24). 
The strong genetic basis for psoriasis suggests that there is some natural selection to preserve 
the trait over generations. One hypothesis is that the upregulated innate immunity in patients 
with psoriasis decreases the risk of certain infections, with scarlet fever (25) and leprosy (26) 
suggested as candidates. 
1.1.4 Epidemiology 
A systematic review (27) on the incidence and prevalence of psoriasis found that incidence 
estimates ranged from 79 to 230 cases per 100,000 person-years; and prevalence estimates 
ranged from 0.9% to 8.5%. No major differences in incidence or prevalence between men 
and women were observed. However, the incidence of psoriasis with age may follow a 
bimodal distribution with peaks observed before and after the fifth decade of life. The 
occurrence of psoriasis appeared to vary by geographic region, with the disease increasing in 
frequency with the distance from the equator. Differences between ethnic groups have also 
been reported with low prevalence found in African Americans compared to Caucasians in 
the United States. The reasons for the geographical and ethnic variation is unknown but likely 
reflect both genetic and environmental factors. The reported variation across studies may also 
reflect differences in study methodology, such as case definition, ascertainment procedures, 
and sampling schemes. (27) 
Comparatively few studies have described long-term trends in the incidence of psoriasis. A 
US study found that the incidence almost doubled between 1970–74 and 1995–1999 (28). 
Furthermore, a meta-analysis of five population based cohort studies in Norway found that 
self-reported prevalence of psoriasis increased with each consecutive survey from 4.8% in 
1979-1980 to 11.4% in 2007-2008 (29). However, a Danish population based administrative 
register study found the incidence to be fluctuating between 2003 and 2012 (30), and a UK 
study observed a slight decline between 1999 and 2013 (31)  
1.1.5 Comorbidities 
Even though the first observed association between psoriasis and another disease – diabetes 
mellitus – was made in 1897 (32), psoriasis was historically viewed as an affliction in the 
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healthy (21, 33). Nevertheless, the notion that the disease may be systemic and associated 
with poor health was also entertained (23). Over the years, psoriasis has increasingly been 
viewed as a systemic inflammatory disorder and has been associated with numerous 
comorbidities including cardiometabolic disease, inflammatory bowel disease, kidney 
disease, cancer, infections and mood disorders (32). The excess risk of comorbidities 
observed in patients with psoriasis appears to be dose-dependent in the sense that patients 
with severe disease are at higher risk than patients with mild disease (32). The pathogenic 
mechanisms for the excess comorbidity burden in psoriasis are unknown but may include 
genetic susceptibility, shared risk factors, and shared inflammatory pathways (32). The 
underlying mechanisms may differ between comorbid conditions (32). 
1.1.6 Impact on patients 
Psoriasis is a multifaceted disease. Clinical manifestations reduce health related quality of life 
(HRQoL), impair the ability to perform daily activities, and affect productivity (2). 
Furthermore, treatment may be unpleasant, time consuming and carry the risk of severe side 
effects (34). 
The lesions in patients with psoriasis may hurt, itch, bleed, or burn (35). Other manifestations 
include skin scaling, erythema and swelling (2). These symptoms affect physical HRQoL 
directly and indirectly through their effect on mobility, vitality, sleep and rest (36). 
The visible disfiguration in patients with psoriasis may trigger negative reactions in the 
patient and others, resulting in impaired emotional functioning, negative body and self-image, 
psychological distress, and disrupted social relationships (36). In a comparison of the impact 
on physical and psychological burden of eleven diseases including cancer, ischemic heart 
disease, and congestive heart failure; only patients with depression or chronic lung disease 
had lower psychological HRQoL than patients with psoriasis (37).  
Psoriasis can affect activities of daily living. For example, clothing, personal hygiene,  
sporting, and sexual activities were reported to be adversely effected in 27% to 56% of 
patients with moderate to severe disease (38). In addition, the effects of the disease extend to 
the professional lives of patients with close to seventy per cent of patients reporting adverse 
impact in this domain (39). 
Psoriasis may affect work productivity. It has been estimated that approximately 35% of 
absenteeism and 45% of presenteeism in patients with the psoriasis result directly from the 
disease. (40)  
It should also be noted that cultural and socioeconomic factors can influence the experience 
and even presentation of symptoms (41), potentially making generalization of disease impact 




Treatment for psoriasis is as yet non-curative and the objective is to control symptoms (2). In 
addition to providing recommendations on the management of skin manifestations of the 
disease, a number of psoriasis treatment guidelines also advice on screening for comorbidities 
such as cardiovascular disease, metabolic syndrome, and depression (42-45). In fact, it has 
been suggested that the multifaceted nature of psoriasis requires a holistic approach that is 
better characterized as management than treatment (46). 
Historically, treatment of psoriasis was very heterogeneous and a review from the early 20th 
century state that “[An] enormous number of medicines … have been used internally or 
externally for psoriasis” (23). Examples include thyroid glands in minced raw, dried, or liquid 
extract form (47, 48); subcutaneous injections of arsenic (21), topical mercury (21), and 
occlusive dressings in the form of vulcanized Indian rubber suits (49). 
Today, three treatment modalities exist: topicals; phototherapy; and systemics (2). Treatment 
choices are individualized and reflect disease severity, lesion characteristics, recalcitrance, 
comorbidities and preferences of the patient (45). Due to potential serious adverse events, 
treatment risk-benefit profile is an important factor in clinical decision making (45). 
Historically, switching, rotating and combining therapies were common as physicians sought 
to restrict cumulative dose and side effects (50). Frequently used psoriasis treatments are 
described in terms of mode of administration, frequency of administration, and effectiveness 








Frequency of administration during maintenance 
treatment  
Effectiveness 
Corticosteroids  Topical Once or twice per day 60% 
Vitamin D derivatives Topical Once or twice per day 45% 
Calcineurin inhibitors  Topical Twice per day 30% 
UVB Phototherapy Three times per week for seven to twelve weeks b 70% 
PUVA Phototherapy Two to three times per week for nine to fifteen weeks c 90% 
Acitretin  Oral  Once per day 15% 
Cyclosporine  Oral  Twice per day 45% 
Methotrexate  IV, IM, SC or oral  Once per week 50% 
Apremilast Oral  Twice per day 30% 
Adalimumab  Subcutaneous Every second week 70% 
Etanercept  Subcutaneous Once or twice per week 50% 
Infliximab  Intravenous Every six to eight weeks 80% 
Ustekinumab  Subcutaneous Every twelve weeks 70% 
Secukinumab Subcutaneous Every month 80% 
Ixekizumab Subcutaneous Every four weeks 90%a 
Brodalumab Subcutaneous Every two weeks 90%a 
Tildrakizumab Subcutaneous Every twelve weeks 65%a 
Guselkumab Subcutaneous Every eight weeks 85%a 
Risankizumab Subcutaneous Every twelve weeks 90%a 
Dimethyl fumarate Oral Three times per day 30%a 
Note: Efficacy (Proportion of patients who achieve at least  75% reduction in PASI [PASI75]) were adapted from Bohencke and Schon (1) 
unless otherwise noted. Mode of administration and frequency during maintenance treatment were obtained from FASS (51) unless otherwise 
noted. a From Sawyer et al 2019 (52); b from Singh et al (2016) (53); c from Farahnik et al. (2016) (54). IV stands for intravenous, IM stands 
for intramuscular, and SC stands for subcutaneous. 
Swedish treatment guidelines were updated in 2019 (45). The guidelines recognize that 
treatment choices should be customized to the patient, but patients with limited disease may 
generally be treated with topical agents. If the disease is more severe, the guidelines stipulate 
treatment with phototherapy or systemics. Methotrexate is recommended in patients with 
severe disease. Tumor Necrosis Factor (TNF) inhibitors are indicated for the same 
population, albeit as a slightly lower priority. Interleukin inhibitors are recommended for 
patients who have failed TNF inhibitors, or in whom TNF inhibitors are not relevant 
alternatives. Apremilast may also be an alternative for this patient population. (45) 
Topical treatments include creams, ointments, and foams that are applied to the areas of skin 
affected by psoriasis (55). They are often effective with relatively benign side-effects profile, 
albeit skin atrophy is a theoretical concern with long-term use of topical corticosteroids (55). 
Topicals may also be used as augmentation to other treatments (56). One disadvantage is that 
their application may be time consuming and have adverse cosmetic properties, resulting in 
low adherence (57) and almost 50% of first prescriptions for a previously untried topical 
medication for psoriasis are never collected from the pharmacy (58). The most frequently 
used topicals for psoriasis are corticosteroids, vitamin D3 analogues, and fixed dose 
combinations of vitamin D3 analogues and corticosteroids (55). Other topicals such as 
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retinoids (tazarotene), coal tar, and dithranol are available, but used less frequently given their 
comparatively burdensome applications (55).  
Phototherapy comprise three main types: Broadband ultraviolet (UV) A, Narrowband UVB, 
and photochemotherapy UVA (PUVA) (59). UVA and UVB refers to different wavelengths 
of the light: UVA ranges between 320 and 400 nanometers (nm); UVB ranges between 290 
and 320 nm, and narrowband UVB has a wave-length around 311 nm (59). The mechanism 
of action of phototherapy is not completely understood (60).  
UVB light is administered in a light box for a brief duration (seconds to minutes) (53). 
However, preparations and post administration activities result in appointments lasting fifteen 
to twenty minutes (53). A UVB treatment course generally consists of three sessions per 
week, with a minimum of twenty-four hours between sessions (53). Each course consists of 
twenty to 36 sessions (53). Potential long-term safety concerns with UVB include cosmetic 
skin ageing and skin cancer. However, UVB appears safe with no excess risk of melanoma 
and non-melanoma skin cancer observed over five years in 3,867 patients (61). 
Psoralens, a group of photosensitizing compounds, increase the sensitivity of the skin to UV 
light and are therefore used with UV light as therapy for psoriasis (54). Psoralens are 
available as orals or bath salts and are usually administered prior to UVA exposure. Similarly 
to UVB, the light is administered for a short duration (seconds to minutes) in a light box. 
However, preparations differ from UVB. If psoralen is administered orally, the patient should 
ingest a psoralen 75 minutes before the appointment and if bath PUVA is administered the 
patient should soak in a bathtub with a mixture of hot water and the psoralen for thirty 
minutes prior to light exposure. PUVA is very effective (Table 1) but is associated with long-
term increased risk of skin cancer and short-term side effects including burning, itching and 
nausea. (54) 
Systemic treatments for psoriasis comprise traditional small molecule systemics such as 
methotrexate, acitretin, and cyclosporine; novel small molecule systemics such as apremilast 
and dimethyl fumarate; and biologics (45). The distinction between small molecules and 
biologics is that small molecules are generated using chemical synthesis whereas biologics 
comprise large and complex molecules, generally antibodies, produced by living cells (hence 
the term biologic) (45). Administration, and effectiveness differ between systemic treatments 
(Table 1), but one common feature for all systemic treatments, except acitretin, is that they 
have direct immunosuppressive effects. Whilst efficacy differs between systemic treatments, 
a meta-analysis of safety found no significant differences between systemic treatments for 
serious adverse events (62). However, the evidence was generally short-term and of low to 
moderate quality (62). 
1.2 OBSERVATIONAL RESEARCH 
The studies presented in this thesis are observational and patients are followed over time. 
This section contextualizes these types of studies and discusses broad methodological issues 
relevant to them. 
 
 9 
1.2.1 Study design 
The design of a study should reflect the research objective and ethical considerations, but 
necessarily also reflect resource constraints, and data availability (63). There are numerous 
categorization schemes for study design (64). For example, studies may be categorized 
according to objective (e.g. prevention, diagnosis, or treatment), investigative purpose (e.g. 
descriptive or analytical), use of study results (e.g. basic or applied), data collection (e.g. 
primary or secondary), or role of investigator (e.g. observational or experimental) (64).  
A parsimonious high-level categorization scheme divides studies into three main types: 
Theoretical, Descriptive, and Analytical (65); with each study type further divided into 
subcategories (Figure 2). Theoretical studies explain or develop understanding of processes 
that occur for participants; descriptive studies describes outcomes in a group; and analytic 
studies quantifies the relationship between variables, e.g. treatment and outcome (65). Studies 
can fall under more than one category (65). For example, baseline characteristics in an 
observational cohort study may describe the state of a population and therefore have a 
descriptive purpose, whereas exposure during follow-up may be related to outcomes for an 
analytic purpose. 
Figure 2 Parsimonious classification of study design. Adapted from Glasziou and Heneghan (2009) (65). 
The studies in this thesis are observational cohort studies and therefore fall into the 
highlighted category in Figure 2. The studies are observational given that patients are not 
assigned a specific treatment or exposure as part of the study, and they are cohort studies 
because patients are identified at one point in time and followed thereafter. However, it 
should be noted that they have both analytical and descriptive objectives.  
Cohort studies may be classified as prospective and retrospective (66). However, whether a 
cohort study is prospective or retrospective is a question of perspective: Data may be 
collected prospectively while the analysis of the data (e.g. selection of patients and study 
design) may be retrospective (66). 
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1.2.2 Populations and sampling 
Knowledge of characteristics and associations in a population informs expectations on 
members of that population. Obtaining data for an entire population is often impracticable 
and prohibitively expensive. Therefore, data from a sample (a subset of a population) is used 
to make inferences (draw conclusions) about the population (67): The findings from the 
sample is generalized to the population.  
A framework for sampling in human studies suggested in Hernan (2016) (68) is shown in 
Figure 3. In this framework, the population of interest is called target population; and the 
characteristic of interest is called parameter. The target sample is a defined subset of the 
population for which the researcher wishes to make inferences. Ideally, the target sample is 
identified from the target population using a random process. Under random sampling, the 
estimate of the population parameter is expected to be correct on average and uncertainty 
around the estimate can be quantified. (68). True random sampling is often difficult and 
investigators frequently rely on non-random sampling procedures they believe will generate a 
sample that is representative of the target population (68). However, the actual sample may 
deviate from the target sample depending on selection mechanisms that are outside the 
control of the researcher. For example, women may be more likely than men to participate in 
a research study. In theory, the representativeness of the actual sample to the target sample 
may be explored quantitatively to assess and improve generalizability (69). However, 
important information from non-participants are frequently missing, making an informed 
quantitative assessment of representativeness difficult (69). Similarly, in the absence of 
external validation, transportability of the parameter estimate to another target population is 
also uncertain. Furthermore, generalizability and transportability may be problematic when 
conditions in a study are dissimilar to conditions outside the study, resulting in that 
participants alter their behavior or are otherwise affected by the study setting (70, 71). 
The terminology used in the framework discussed above is not universal. For example, the 
terms target population, generalizability, and transportability can be referred to as source 
population, internal validity, and external validity or generalizability, respectively (72).  
Figure 3 Framework for participant selection in clinical studies. Adapted from Hernan (2016) (68). 
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1.2.3 Variables and distributions 
Data to estimate population parameters are obtained from a sample in the form of variables. 
Variable have two defining characteristics: They provide descriptive attributes, and they can 
vary between observations (73).  
Variables vary. Therefore, they may be described by mathematical functions known as 
probability distributions (74). Probability distribution assigns probabilities for each possible 
value that a variable may take (74). Based on subject matter knowledge and the observed data 
for a variable in a sample, the shape and form of the probability distribution may be assumed 
(75). A probability distribution is defined by its parameters and the observed data on a 
variable in an actual sample can be used to estimate the parameters of a distribution in the 
target population (68). 
Estimates of target population parameters may be interesting in themselves. In addition, they 
are often used to make comparisons. For example, one can estimate the probability that the 
mean of one distribution is equal or larger than a given value, or that the observed probability 
distributions in two samples are generated by the same underlying probability distribution, 
e.g. to assess whether the expected outcome observed in one group is different from the 
expected outcome observed in a second group.  
In addition to representativeness of the target population, a key assumption for many 
procedures for inferential statistics is that the variable of interest is independent and 
identically distributed. In this context, independent means that observations do not affect each 
other; and identically distributed means that all values should come from the same 
distribution (76) –  there should be no trends in the data, e.g. patients recruited late in a study 
should not be systematically different from those recruited early in a study. 
Regardless of the probability distribution of the variable in the population, the central limit 
theorem (CLT) posits that the sampling distribution of the mean (the distribution of means 
from repeated samples from the population) will be approximately normal, assuming that the 
sample size is sufficiently large (77). A rule of thumb is that a sample of thirty is sufficiently 
large for the sampling distribution of the mean to be approximately normal (78). However, 
this rule of thumb is debated and larger sample sizes may be required for heavily skewed 
distributions (78).  
1.2.4 Precision and bias 
An important consideration for many descriptive and analytical studies is to estimate the 
relevant population parameter(s) with as little error as possible (72). Errors in estimation can 
be classified into two groups: Random and systematic errors (72). Random error affects the 
precision of the estimate whereas systematic error affects the generalizability from the actual 
sample to the target population (72). 
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1.2.4.1 Random errors 
Conceptually, random error may reflect (i) chance, or (ii) insufficient knowledge of causes 
and effects. For example, if an observer knew all the physical forces that affect a coin toss, 
she should be able to perfectly predict the outcome of the toss. However, in most 
circumstances, she does not know those forces and therefore the outcome appears random to 
her. A synthesis of the two views is that random variation is the part of reality we cannot 
predict. (72) 
Given the random variation in a variable, the precision of a parameter estimate is uncertain 
(72). Assuming that the sample is randomly drawn from the population, statistics can be used 
to derive measures of this uncertainty. Confidence intervals is a frequently used measure of 
uncertainty for the parameter estimate. A confidence interval for a mean can be defined as: 
“If a series of samples are drawn and the mean of each calculated, 95% of the means would 
be expected to fall within the range of two standard errors above and two below the mean of 
these means” (79). However, it may be noted that even if the notion of random sampling is 
correct, confidence intervals may be inaccurate given that other sources of uncertainty, such 
as measurement error, affect precision (80).  
1.2.4.2 Systematic errors 
In the Merriam-Webster dictionary, bias is defined as any “tendency which prevents 
unprejudiced consideration of a question”. In research, bias arise when “systematic error [is] 
introduced into sampling … by selecting or encouraging one outcome … over others” (81). 
Bias is problematic because it may lead to false associations or failure to identify true 
relationships (82), distorting our understanding and potentially misdirecting our actions (83). 
Biases are numerous and a review from 2004 provide an explicitly non-exhaustive list of 
more than sixty biases (84). The terminology used to describe bias differ by fields. For 
example, the term “confounding by indication” frequently used by epidemiologists refers to 
the same concept as the term “selection bias”, more frequently used by statisticians (85). 
Several classification systems for biases exist (84). The discussion below adopts a frequently 
used classification system that groups biases into three categories: Selection bias, information 
bias and cofounding (86).  
Selection bias arises when the actual sample is not representative of the target population on 
relevant factors (84). Therefore, in descriptive studies, selection bias affects the 
generalizability of the actual sample to the target population reflecting that the parameter 
estimates from the actual sample differs from the true parameter in the target population (68). 
In analytical studies where the objective is to obtain unbiased estimates of relationships 
between exposure and outcome, selection bias may occur when sample selection is affected 
by both exposure (or a cause of the exposure) and the outcome (or a cause of the outcome), 
resulting in absence of comparability between groups being studied (85). Even if groups are 
comparable, selection bias may affect the estimates of analytical studies for the same reason it 
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impacts descriptive studies: the actual sample may not be representative of the target 
population (87). 
Information bias can occur when information used in the analysis is measured or recorded 
erroneously (72). The impact of information bias depends on whether the measurement or 
classification error is the same or different across exposure and/or outcome. In a descriptive 
study, systematic measurement errors will result in lack of generalizability from the actual 
sample to the target population. For analytic studies, the impact of information bias is more 
complex and depends on whether the measurement errors affect the exposure and/or the 
outcome and whether it is the same in all study groups (non-differential misclassification) or 
differs between study groups (differential misclassification). In the common case of two 
exposure groups and an outcome without measurement error, the expected bias from non-
differential misclassification of exposure is towards the null, i.e. the relationship between 
exposure and outcome will be underestimated. When misclassification is worse than would 
be expected of a random process, e.g. through inverse coding of a variable during data entry, 
the bias may be away from the null, but in the opposite direction. (72) 
Confounding bias affect analytical studies. Confounding has been defined as the existence of 
common causes of exposure and outcome (85) and may result in erroneously estimated 
associations between exposure and outcome (72). However, it is not sufficient that a variable 
is associated with both exposure and outcome to be a confounder (72). For example, when 
exposure has an effect on an outcome, a variable that correlates with exposure will also be 
associated with outcome, even though it does not confound the relationship between exposure 
and outcome. Therefore, it is important to carefully consider the causal mechanisms when 




2 LITERATURE REVIEW 
2.1 CLINICAL COURSE OF PSORIASIS 
Textbooks in dermatology and psoriasis describe the clinical course of psoriasis as varying 
and unpredictable: It is frequently chronic, but may also wax and wane, and spontaneous 
remissions of varying lengths occur (8, 88-91). Several textbooks also state that 
understanding of the course is limited due to absence of prospective observational studies that 
describe the course from onset (8, 88, 90). This notion is also supported by three position 
papers on the research agenda in psoriasis, which state that prospective observational studies 
on the course of psoriasis from onset should be a research priority (92, 93).  
A review of the literature demonstrate that a number of studies have described the course of 
psoriasis using cross-sectional or retrospective designs. Outcomes measures, perspectives, 
and information provided differ among studies, making a coherent overview difficult. 
Furthermore, the signs and symptoms of psoriasis are affected by treatment and given 
developments in medicine over time, the validity of old data to the present may be 
questionable1. Another challenge is that the course may be confounded by age. For example, 
if symptoms improve with age, the disease course will appear benign even though it is driven 
by ageing rather than disease duration. However, for the individual patient, such as 
distinction may be of limited consequence.  
Table 2 presents on overview of 14 studies published the last one hundred years that 
explicitly aimed to describe the course or prognosis of psoriasis. The studies indicate that a 
minority of patients may achieve sustained remission, even without treatment. For the 
majority of patients, symptoms are constant, and for a minority severe. 
                                                
1 Romanus (1945) also noted this point, but did not consider it problematic reflecting his view that treatment was 
standardized and had changed little since 1878 when chyrsarobin (dithranol/anthralin) was introduced. 
Thereafter the treatment armamentarium in psoriasis has expanded more rapidly, arguably rendering 



















Hippler (1932) (94) Germany Na Chart review and survey 1925-1931 Na 1-7 442 
Complete remission for 1-3 years: 5% 
Intermittent complete remission: 8% 
No remission: 88%  
Hallam (1934) (95)a England Na Chart review and survey 1919-1925 No 9-15 43 Complete remission since index: 9% 
Weinsheimer (1937) (96)a Germany Na Chart review and survey 1928-1934 Na 2-9 321 Complete remission since index: 16% 
Romanus (1945) (14) Sweden Na 
Chart review and 
examination 
1892-1922 Subgroup 20+ 232 
Complete remission since index: 21% 
Intermittent complete remission: 19% 
No remission: 60% 
Diedy (1951) (97) Switzerland Na 
Chart review and 
examination 
1906-1935 Na 15-45 49 
No symptoms: 17% 
Mild symptoms: 38% 
Moderate symptoms: 24% 
Severe symptoms: 21% 
Dorn (1957) (98) Germany Na Chart review and survey 1953-1955 No 2-5 312 
Complete remission since discharge: 7% 
Intermittent mild symptoms: 4% 
Intermittent moderate symptoms: 30% 
Intermittent severe symptoms: 14% 
Constant mild symptoms: 6% 
Constant moderate symptoms: 25% 
Constant severe symptoms: 14% 
Lomholt (1963) (99) 
Faroe 
Islands 
Na Examination and survey Na No Na 207 
Complete remission: 4% 
Mild symptoms: 32% 
Minor spread: 37% 
Major spread:16% 
Severe onset followed by minor eruptions: 11% 
Molin (1973) (100) Sweden Na Chart review and survey 1957-1966 No 4-13 300 




Very severe: 2% 
Farber (1974) (101) USA Na Survey Na Na Na 5,355 Ever complete remission without treatment: 39% 
Martin (1996) (102) USA Guttate Prospective study 1982 Yes 10+ 15 Chronic plaque psoriasis: 33% 
Kaur (1997) (103) India Na Survey Na Na Na 1,220 
Ever complete remission during a year: 35% 
Improved with treatment: 61% 
Never free of disease: 4% 
Ferrandiz (2001) (104) Spain Na 
Survey and clinical 
examination 
Na Na Na 1,774 
Variable course: 39% 
Consistent course: 61% 
Ko (2006) (105) 
South 
Korea 
Guttate Chart review and survey 1980-2004 Yes 1.5-19 36 
Complete remission: 61% 
Chronic plaque psoriasis: 39% 
Sakai (2007) (106) Japan Na 








Note: aQuoted from  Romanus (1945) (14). 
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It has been argued that placebo arms in RCTs provide some information on the short-term 
course of psoriasis without treatment (107). The majority of patients in placebo arms in RCTs 
experience minor change (107). However, a minority of patients improve drastically: For 
example, Ambikaibalan (2020) estimated the proportion of placebo treated patients who 
experienced 75% and 90% improvement in disease severity (measured using the Psoriasis 
Area and Severity Index [PASI]) at 5%, and 2%, respectively (108). However, it is uncertain 
whether those improvements would have taken place outside the trial setting. Siemens 
(1954)2 had a similar approach and withheld treatment from 19 hospitalized patients with 
psoriasis for one month (109). Six of the 19 patients showed pronounced improvement by the 
end of the month (109).  
In terms of prognostic factors for the disease course, early onset has been associated with  
severe disease course (110). However, this finding has not been replicated in all studies (111). 
Male sex (106), major eruption at onset (99), and high BMI (106) have also been associated 
severe course. Short disease duration (14), early treatment (33), and limited initial spread (99) 
have been associated with mild disease course. 
2.2 CAUSE-SPECIFIC MORTALITY 
The direct mortality impact from psoriasis is practically zero (8). However, a recent 
systematic review and meta-analysis of observational studies found that psoriasis was 
associated with excess all-cause mortality (RR: 1.21; 95% CI: 1.14 to 1.28) (112). The excess 
mortality was dose dependent in the sense that severe psoriasis carried higher risk than mild 
psoriasis: RR: 1.13 (95% CI: 1.09 to 1.16) for mild disease and RR 1.52 (95% CI: 1.35 to 
1.71) for severe disease (112). A number of studies have also explored specific causes of 
death including cardiovascular mortality (113-117) deaths related to alcohol (118, 119) and 
smoking (118, 119), suicidality (120), and infection (121). 
Studies that systematically explore the components of all-cause mortality in patients with 
psoriasis compared to the general population have two benefits. Firstly, they can identify the 
causes of death with the highest absolute and relative risks, informing prevention efforts. 
Secondly, they may identify hitherto unknown causes of deaths with risks that differ between 
patients with psoriasis and the general population. However, they are exploratory in nature 
and multiple testing may result in chance findings.  
In addition to the study in this thesis, five studies that systematically estimated the 
components of all-cause excess mortality in psoriasis were found in the literature (122-126). 
However, two Danish studies (125, 126) partially included the same population. Therefore, 
four studies are described in Table 3. The studies have some important differences. Firstly, 
the grouping of causes of death differ. They are grouped either by ICD-10 chapters or by 
classifications from agencies, such as the US Centers of Disease Control and Prevention 
                                                
2 Quoted from Lomholt (1963). 
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(CDC). Furthermore, the studies differ in definition of psoriasis, and severity grouping. 
Nevertheless, commonalities exist: All studies were performed on secondary data assets, 
using either administrative data or electronic medical records databases, and mean age at 
study cohort entry was similar across studies, ranging from 47 to 53. 
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Table 3 Overview of studies that systematically estimated cause specific excess mortality in patients with psoriasis. 
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176,858 a 2,524/a 2016 NA Age and sex 
Note: Salaheden et al (2015) (125) also reported cause-specific mortality for Denmark, However, Skov et al (2019) (126) is presented here given that it provides more recent data. a No specific control population: age and sex 
standardized mortality ratios used to estimate excess risk. bOnly for all-cause mortality, not for specific causes of death. 
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Table 4 presents the direction and statistical significance of the associations between 
psoriasis and specific causes of death presented in the studies. Given that the causes of death 
were grouped differently between the studies, estimates are difficult to compare directly. 
However, it may be noted that all cohorts reported statistically significant increases in 
cardiovascular mortality, diabetes and metabolic mortality, and cancer mortality.  
Table 4 Summary of results in four studies that systematically estimated cause specific excess mortality in patients 
with psoriasis. 
Cause of death 
Abuabra (2010) 
(122) 
Lee (2017) (124) Skov (2019) (126) 
Colaco (2020) 
(123) 
Infection +* +* +* + 
Cancer +* + +* +* 
Diabetes and metabolic disease +* +* +* +* 
Mental and behavioral disorder . -* +* +* 
Neurological disease +* + +* + 
Cardiovascular disease +* +* +* +* 
Respiratory disease +* + +* +* 
Diseases of the digestive 
systems / liver disease 
+ +* +* +* 
Kidney / genitourinary disease +* +* +* + 
Injury, poisoning and other 
external causes 
+ -* +* . 
Suicide / Intentional self-harm + +* +* . 
Unknown/Missing +* . +* . 
All-cause . +* +* +* 





2.3 TREATMENT PATTERNS 
Treatment patterns is a broad term. For example, it may describe treatment uptake in a 
population, drug survival or persistence, switching, or adherence. In the current study, it is 
used as an umbrella term for five events that describe aspects of effectiveness and treatment 
outcomes: Persistence, switching, augmentation, restart after discontinuation, and insufficient 
treatment result.  
A systematic review on endpoints in real-world effectiveness studies on biologic treatment in 
psoriasis (127) showed that most real-world studies used either clinical end-points or 
persistence to estimate effectiveness, but a handful of studies also incorporated switching, 
dose increase, augmentation, and restarts into outcome definitions (127). Especially 
persistence, defined as time from start to discontinuation of treatment has been extensively 
studied, primarily for novel systemics and biologics (128), but also for traditional systemics 
(129). Most data, especially from Europe, have been derived from clinical registers and 
retrospective chart reviews, but studies on administrative data using refill patterns have also 
been published, e.g. in Sbidian et al (2019) (130); and the relative merits of the different 
approaches have been debated (131, 132).  
Data on real-world effectiveness of topicals are scarce, potentially reflecting challenges in 
operationalizing treatment events given the on-demand nature of topicals. However, the data 
that do exist indicate that primary persistence is poor with nearly half of new prescriptions 
never redeemed (58).  
2.4 ECONOMIC BURDEN 
We identified four studies that estimated aspects of economic burden of psoriasis in Sweden.  
Ghatnekar et al 2012 (133) presented a cross-sectional survey of societal costs during one 
month in 164 patients with psoriasis recruited in two Swedish dermatology clinics between 
September and December 2009. Mean total costs per patient were estimated at EUR 994. 
Costs were presented stratified by most potent treatment received: For patients whose most 
potent treatment was topicals, phototherapy, traditional systemics, and biologics, mean costs 
were estimated at EUR 369, EUR 1,274, EUR 1,085 and EUR 1,709 respectively  The study 
did not observe a clear relationship between costs and clinical severity, measured by PASI, or 
costs and HRQoL measured by DLQI. (133) 
Ekelund et al (2013) (134) enrolled 443 patients with psoriasis based on PASI criteria: 153 
with PASI<8, 128 with 8 ≤ PASI ≤ 12, and 162 with PASI>12. Mean costs were estimated 
using a questionnaire with a one year look-back period. The mean annual direct and indirect 
costs were estimated at EUR 2,169 and 1,230, respectively. Whilst PASI was not a significant 
cost driver in the study, DLQI, PsA, and systemic treatment were positively and significantly 
associated with mean annual costs. (134) 
Direct and indirect costs for psoriasis in Sweden 2006 and 2009 were presented in Norlin 
(2015) (135). The study identified patients who had a specialist outpatient visit or inpatient 
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episode with psoriasis as primary or secondary diagnosis; or dispensed a prescription of a 
medication with calcipotriol in the relevant years. Direct costs in the study comprised 
specialist outpatient visits to a Medical Doctor and inpatient treatment of psoriasis (both with 
a primary diagnosis of psoriasis), and topicals, traditional systemics, and biologics used to 
treat psoriasis. Indirect costs were estimated with the human capital approach and the 
proportion of indirect costs attributable to psoriasis estimated by comparing patients with 
psoriasis to age, sex, and residency matched controls. Total mean direct cost per patient in 
2006 and 2009 were estimated at EUR 743, and EUR 855, respectively. Total mean indirect 
cost per patient in 2006 and 2009 were estimated at EUR 3,509, and EUR 3,010, respectively. 
In 2009, total mean direct (indirect) costs for patients who were treated with topicals, 
systemics, and biologics as most potent treatment were estimated at EUR 315 (EUR 2,238), 
EUR 801 (EUR 5,380), and 12,786 (EUR 10,035), respectively. (135)  
Lövendahl et al (2016) (136) estimated mean direct and indirect annual costs in patients with 
psoriasis and PsA from 2008 to 2011 using the Skåne Health Care Register (SHCR), a 
population based health care register in the Skåne Region (~1.3 million inhabitants) in 
Southern Sweden. Patients with psoriasis or PsA were identified using ICD-10 codes in any 
type of care (primary, specialist outpatient, and inpatient care) between 1998 and 2007. Mean 
annual costs due to psoriasis and PsA were estimated using two approaches. In the first 
approach, the mean difference in costs between patients with psoriasis or PsA and age, sex, 
and residency matched controls without psoriasis or PsA was estimated. In the second 
approach, only health care resource use and sickness episodes with an ICD-10 code for 
psoriasis or PsA, and treatments used for the two conditions were considered. Among the 
12,562 patients with psoriasis and 2,721 patients with PsA, mean health care costs were 
estimated at EUR 3,717 and EUR 6,186, respectively. The mean annual incremental direct 
costs in patients with psoriasis or PsA compared with the controls were estimated at EUR 
1,724. Using the second approach, the mean disease specific costs were estimated at EUR 
400 for psoriasis and EUR 2,866 for PsA. The mean annual indirect costs were estimated at 
EUR 4,666 in patients with psoriasis and EUR 10,566 in patients with PsA. The proportions 
of indirect costs directly attributable to the diseases was estimated at 82% for patients with 
psoriasis, and 89% for patients with PsA. (136) 
2.5 RELATIVE EFFECTIVENESS OF ADALIMUMAB, ETANERCEPT, AND 
METHOTREXATE 
The advent of biosimilar adalimumab and etanercept may render biologics viable first line 
systemic treatment in psoriasis (137). Relative effectiveness of adalimumab and etanercept 
compared to methotrexate, the most common systemic treatment in current clinical practice, 
is an important consideration for such a change in treatment paradigm.  
Two clinical trials have demonstrated that adalimumab is more effective than methotrexate. 
The CHAMPION study was a double-blind RCT on 108 patients treated with adalimumab, 
110 patients treated with methotrexate, and 53 patients treated with placebo (138). After 16 
weeks, the proportion of patients who reached the primary end-point, at least seventy-five 
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percent reduction in PASI from baseline (PASI75), was estimated at 80% for adalimumab. 
36% for methotrexate (p<0.001 vs adalimumab), and 20% for placebo (p<0.001 vs 
adalimumab) (138). In pediatric psoriasis, adalimumab and methotrexate were compared in a 
double-blind RCT on 75 patients (139). After 16 weeks, a higher proportion of patients 
treated with adalimumab achieved the co-primary end-point PASI75 compared with patients 
treated with methotrexate (58% vs 32%; p=0.027) (139). No RCTs have directly compared 
etanercept to methotrexate. A Cochrane Collaboration Systematic Review and meta-analysis 
of RCTs comprising 140 studies on a total of 51,749 randomized participants showed that 
adalimumab and etanercept were more effective than methotrexate in achieving at least 
ninety percent reduction in PASI from baseline (PASI90) (62).  
In terms of real-world data, three studies have estimated and compared the drug survival of 
adalimumab, etanercept, and methotrexate. A Spanish study using the BIOBADERM register 
estimated median drug survival for adalimumab at 1.68 years, etanercept at 1.21 years, and 
methotrexate at 1.01 years (140). The differences in drug survival between adalimumab and 
methotrexate, but not between etanercept and methotrexate, were significant at the five 
percent level (140). Another Spanish prospective observational study, the SAHARAH, 
enrolled patients with moderate to severe psoriasis treated with systemics (141). Among the 
87, 90, and 97 patients treated with adalimumab, etanercept and methotrexate, the 12 (24 
months) drug survival was estimated at 68.4% (53.9%), 79.3% (66.3%), and 69.5% (51.6%), 
respectively (141). No statistical tests were conducted for differences, but the confidence 
intervals for the drug survival rates were overlapping (141). A retrospective chart review 
from a single German center comprising 357 patients estimated one year drug survival for 
adalimumab, etanercept, and methotrexate at 70%, 60%, and 43% ,respectively (142). No 
statistical significance tests for these differences were conducted (142). 
Three real-world studies have estimated effectiveness of the three treatments using s-PGA 
and PASI as outcomes. In a US cross-sectional study on patients with plaque psoriasis, the 
proportion of patients who were clear or almost clear from lesions on adalimumab (n=152), 
etanercept (n=191) and methotrexate (n=174) were 47.7%, 34.2%, and 23.8%, respectively 
(143). Both before and after adjusting for confounders, the differences between adalimumab 
and methotrexate, and etanercept and methotrexate were statistically significant at the five 
percent level (143). An Italian prospective register study estimated outcomes in patients aged 
65 or more treated with adalimumab (n=18), etanercept (n=83), or methotrexate (n=74) (144). 
At week 12 after treatment initiation, the proportions of patients on adalimumab, etanercept, 
and methotrexate who achieved PASI75 were 65%, 64%, and 49%, respectively (144). No 
tests for the statistical significance of the observed differences were conducted (144). In an 
Italian prospective study including 43 patients on methotrexate and 58 patients on etanercept, 
the mean percentage improvements at six months with etanercept and methotrexate were 




3 RESEARCH AIMS 
There has been considerable advances in the treatment of psoriasis and our understanding of 
its pathogenesis has improved. Nevertheless, knowledge of the clinical course of psoriasis is 
limited and comes from retrospective and cross-sectional studies. Therefore, prospectively 
collected data on the disease course and its predictors holds substantial interest to the medical 
community at large, especially to clinicians whom patients are likely to see at disease onset. 
Such data can help practitioners to communicate more accurate expectations of the long-term 
prognosis and disease impact; and can also help to identify patients who may have the most 
to gain from frequent follow-up. 
Information on cause-specific mortality in psoriasis may identify the most lethal 
comorbidities in both absolute and relative terms. Furthermore, data on cause-specific 
mortality stratified by severity may improve our knowledge on the relative importance of 
comorbidities in the two populations and inform discussion on factors associated with the 
onset and severity of psoriasis. 
Understanding the economic burden of the disease may provide information on subgroups 
with unmet need, areas for potential improvement, and may contribute with information 
relevant to setting research agenda and allocating resources. Data on the economic burden of 
psoriasis in a Swedish setting are scarce and the data that do exist do not include all relevant 
costs, or do not stratify patients by disease severity.  
Many studies have reported on persistence of novel systemic treatment and biologics in 
psoriasis in Europe. However, other aspects of treatment patterns such as switching and 
augmentation are less frequently reported. Data on topicals and traditional systemics are also 
scarce. In addition, few studies have described treatment patterns using population based 
administrative registers in a European setting. More comprehensive data on treatment 
patterns, especially for topicals and traditional systemics, may improve accuracy of 
expectations on treatment and can inform clinical decision-making. With the advent of 
biosimilars, biologics may be feasible alternatives as first line systemic treatment in 
moderate-to-severe psoriasis. Improved understanding of the relative effectiveness of 
adalimumab, etanercept, and methotrexate is therefore an important step in evaluating the 
relative merits of biosimilars as first line systemic treatment. 
To these ends, the specific objectives of this thesis are to: 
1. Describe the clinical course of psoriasis and its predictors. 
2. Estimate cause-specific excess mortality in patients with psoriasis. 
3. Estimate the healthcare and societal economic burden of psoriasis. 
4. Describe the real-world treatment patterns in psoriasis. 






4 MATERIALS AND METHODS 
4.1 STUDY SETTING 
Healthcare in Sweden is predominately funded through taxes with universal access and 
limited co-payment (maximum of SEK 2,250 [approximately EUR 244] for medication per 
year; and EUR 112 for health care visits) (146, 147). Healthcare provision is decentralized to 
21 regions and predominately publically funded (84%) with user fees and private insurance 
financing 15% and 0.6%, respectively (146). Some health care is provided by the 
municipalities such as care in special housing and home care (146). 
Medical doctors have free prescribing rights and clinical thresholds or applications do not 
hinder access to psoriasis treatments (148). Systemic treatment of psoriasis is predominately 
provided by dermatologists (45). 
4.2 DATA SOURCES 
This thesis comprises manuscripts from three studies using different data sources: The 
Stockholm Psoriasis Cohort (SPC) (Manuscript 1), the Psoriasis REtrospective STudy 
(PSOREST) (Manuscripts 2, 3, and 4), and DermaReg-Pso (Manuscript 5). 
The SPC was a prospective observational study enrolling patients with recent onset psoriasis 
and controls; PSOREST identified all patients with a diagnosis of psoriasis in Region Skåne 
and Västra Götaland using administrative databases; and DermaReg-Pso is a register 
following patients on systemic treatment for psoriasis in Stockholm. Both SPC and 
PSOREST comprised linkages to other databases. 
4.2.1 Stockholm Psoriasis Cohort 
The Stockholm Psoriasis Cohort (SPC) is a prospective observational study on patients with 
recent onset psoriasis and population matched controls. Patients above 15 years of age with 
first onset of psoriasis lesions on non-hairy skin within the last 12 months were eligible for 
study inclusion. 
Patients were mainly recruited from the Stockholm area, Sweden, between 2000 and 2005. 
Patients were referred from dermatology clinics, general practitioners, school nurses, sexual 
health centers, and youth clinics. The study was also advertised in daily newspapers and in 
the magazine and website of the Swedish Psoriasis Association. Individuals were screened 
via a telephone interview conducted by a dermatologist or a study nurse. Patients who were 
deemed to fulfil the study inclusion criteria were examined clinically by one of two 
dermatologists and patients with a convincing diagnosis of psoriasis were included. 
Individuals with a history of skin symptoms suggesting prior psoriasis were excluded.  
Clinical examinations were performed using standardized forms at enrollment and at ten 
years. The data collected comprised phenotypes and clinical manifestations – both classified 
according to established terminology (149) – history of psoriasis and potential precipitating 
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factors including infection, defined as acute symptoms requiring anti-infective treatment 
within ten days of onset of psoriasis, and stressful life events, defined as events with profound 
effect on the patients within two months of disease onset. A small number of patients were in 
remission at the time of the enrollment examination. For these patients, medical records were 
requested and evaluated to validate the initial diagnosis. Fingernails and toenails were 
examined to assess nail lesions on all patients, albeit only fingernails were included in the 
analysis reflecting that the evaluation of toenails may be complicated by fungal infections.  
Patients with subjective joint problems were seen by a rheumatologist for comprehensive 
joint examination. Relevant patients were also seen by a rheumatologist at ten years for a 
similar joint examination. The rheumatological examinations included evaluation of the 
presence of arthrosynovitis, tenosynovitis, axial enthesitis, peripheral enthesitis, dactylitis, 
and tender and swollen joint counts.  
Genomic DNA was extracted by standard procedures using peripheral blood samples. 
Information from the examinations, interviews, and laboratory analyses were complemented 
with data from medical records, the National Patient Register (NPR), the Prescribed Drug 
Register (PDR), the Causes of Death Register (CDR), and the Total Population Register 
(TPR). 
4.2.2 Prescribed Drug Register 
The PDR contains national prescription data since 2005. Data are available on date of filling, 
ATC-code, name of the drug, and dosage. The register covers all prescription drugs that are 
dispensed at pharmacies. (150) 
4.2.3 National Patient Register 
The NPR contains data since the 1960s on hospital admissions in Sweden. Available 
variables include date and length of stay, diagnoses, surgical procedures, and DRG codes. 
Since 2001, the register also contains data on specialized outpatient care provided by medical 
doctors but with regional differences in quality. (151)  
4.2.4 Cause of Death Register 
The CDR has data on date of death, underlying, and contributing causes of death for 
individuals who were registered in Sweden when they died (152). Practically all deaths in 
Sweden are recorded and 96% of those have a recorded cause of death (152). Using data for 
death in 1995, a study found 77% agreement between the death certificates and case 
summaries for the deceased individuals (153).  
4.2.5 Total Population Register 
The Total Population Register (TPR) is an administrative register held by Statistics Sweden 
with information on sex, birth, death (if applicable), and residency for all subjects resident in 
Sweden from 1961 (154).  
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4.2.6 Skåne Health Care Register 
The SHCR is a regional database with population wide coverage for Region Skåne, (total 
population of 1.3 million) with information derived from electronic medical records and 
administrative procedures since 1998 (146). The data transferred to the SHCR constitute the 
basis for reimbursement and therefore the register should include the vast majority of health 
care contacts across all types of health care reimbursed by the regions. The proportion of 
health care contacts assigned a diagnosis differ between levels of care and types of care 
provider. For physician visits, the proportion of visits in primary care with diagnoses has 
fluctuated between 80% and 100% since 2005 whereas the corresponding proportion for 
specialist outpatient care exceeded 90% over the same period. Registered variables include 
department (e.g. orthopedics, infection, or dermatology), contact type (visit, phone call, e-
mail, or letter), type of caregiver, emergency visit (yes/no), procedure codes, DRG codes and 
reimbursement amount. (146) 
4.2.7 The Vega register 
Similar to SHCR, the Vega register is a regional database with total population coverage 
(155). For reimbursement purposes, all health care visits in the Region Västra Götaland (1.7 
million inhabitants) are registered in VEGA since 2005, with ICD and procedure codes 
prerequisites for reimbursement. Coverage is practically complete for inpatient, outpatient, 
and primary care. (155) 
4.2.8 MIDAS 
Mikrodata för Analys av Socialförsäkringen (MiDAS) is a database with information on 
social insurance payments and is held by the Social Insurance Agency (156). Whilst data are 
available from 1994, changes to the social insurance system have resulted in changes in 
definitions of variables over time (156). 
MiDAS comprise data relating to episodes of social insurance payments. Payment types 
include sick leave (sickness benefit) and disability pension (sickness compensation, activity 
compensation, and early retirement pension). If the type of payment or the degree of absence 
from work changes during an on-going episode, a new episode is registered (156). 
Individuals who cannot work due to an illness or symptoms of a temporary character may be 
paid sickness benefit from the sickness insurance. Eligible for sickness benefit are those who 
are employed or runs a business, actively looks for a job (registered unemployed), or looks 
after a child (on parental leave). Sickness benefit can be paid at the level of 25%, 50%, 75% 
or 100% of a fulltime employment pay (up to a ceiling), depending on the extent of the sick 
leave. For registered unemployed individuals, business owners, and individuals on parental 
leave, sickness benefit can be paid from day two of the sick leave. In contrast, employed 
individuals will first receive sick pay from their employer for a period before receiving 
sickness benefit. The length of this period is 14 days. (156) 
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Activity compensation (under 30 years of age) and sickness compensation (over 30 years of 
age) can be provided to individuals who cannot work full-time due to injury, sickness, or 
disability. Both sickness and activity compensation are re-evaluated at least every third year, 
but individuals who receive sickness compensation should be unlikely to return to full-time 
employment. (156) 
4.2.9 DermaReg-Pso 
DermaReg-Pso is a register enrolling patients who are candidates for systemic treatment in 
the Stockholm region, Sweden. The register started in 2009 and predominately enrolls 
patients from the Karolinska University Hospital and a treatment center in Sundbyberg run by 
the Swedish Psoriasis Association. Clinician and patient reported outcomes (PROs) are 
collected when the patients visit the clinic and stored in a database. Furthermore, at 
enrolment, background variables including age at onset, and heredity are captured. All 
patients provide informed consent prior to enrollment and may opt out from the register at 
any time. Data collected include the Psoriasis Area and Severity Index (PASI) (157), the 
Psoriatic Arthritis Screening and Evaluation questionnaire (PASE) (158), the Dermatology 
Life Quality Index (DLQI) (159), the EuroQol 5 Dimension 3 Level questionnaire (EQ-5D 
3L) (160), the Montgomery–Åsberg Depression Rating Scale - Self-Rating (MADRS-S) 
(161), and clinical and laboratory values. Start and stop dates for treatments are reported by 
the clinician. Discontinuations of a non-permanent nature are also registered.  
4.2.10 Data linkage 
Sweden registries can be linked using personal identification numbers (PINs) specific to each 
Swedish resident (162).  
Both SPC and PSOREST comprise data linkage. For PSOREST, the personal identification 
numbers for all individuals with at least one diagnosis of psoriasis (L40.X) were extracted 
from the SHCR and the Vega register. The PINs of the identified patients were sent to 
Statistics Sweden, which identified controls for each patient based on sex, residency 
(municipality), and birth year (+/- one year). Statistics Sweden also generated Study IDs 
(SIDs) linked to the PINs. Subsequently, Statistics Sweden communicated the PINs and SIDs 
to the participating registries that – based on the PINs – extracted the relevant data, removed 
the PINs and sent the data to the research group with the SIDs. Consequently, the research 
group obtained de-identified but linkable patient-level data from all registries. Furthermore, 
Statistics Sweden provided the research group with a dataset detailing the link between the 
patient and referents.  
For the SPC the process for data linkage was similar to PSOREST. Statistics Sweden 
identified up to six controls for each study participant based on age (+/-1), sex, and postcode. 
The matching date was set to the date of enrolment for the patient in the SPC. Data on health 




The SPC target population was individuals with recent onset psoriasis in Sweden. The target 
sample comprised individuals, aged 15 years or more, with first onset of psoriasis lesions on 
non-hairy skin within the last 12 months from the Stockholm Region, Sweden. The actual 
sample comprised patients from the target sample who volunteered to participate in the study.  
The PSOREST identified patients with a diagnosis (primary or subsequent) of psoriasis in 
primary care, specialist outpatient care, or inpatient care. The target population comprised all 
individuals with psoriasis in Region Skåne or Västra Götaland. The target sample was 
patients with a diagnosis of psoriasis from 2001 to 2010 in Region Skåne and from 2005 to 
2010 in Region Västra Götaland. The actual sample comprised all patients with a registered 
diagnosis of psoriasis in the SHCR and VEGA databases during these periods. 
The DermaReg-Pso enrolls individuals who are candidates for systemic treatment for 
psoriasis in Stockholm, Sweden. The majority of patients are treated at two centers: The 
Karolinska University Hospital and a clinic run by the Swedish Psoriasis Association in 
Sundbyberg. Patients in DermaReg-Pso may have concomitant PSA, but are predominately 
treated for the skin component of the disease. The target population in the DermaReg-Pso are 
patients who are treated with systemics for psoriasis in the Stockholm area Sweden; the target 
sample includes patients treated at the two participating clinics; and the actual sample 
comprises patients from the two clinics who agreed to participate in the register. 
4.4 OUTCOMES AND COVARIATES 
4.4.1 Disease severity 
There are more than  forty instruments for assessing the severity of psoriasis (2). The most 
frequently used severity measure in clinical trials is the PASI, which rates severity on a score 
ranging from 0 to 72, based on assessment of erythema, infiltration, thickness, scaling and 
extent of lesions over four body regions (head, trunk, upper limb, and lower limb) (157). The 
PASI has been criticized for being complicated, non-linear, and having low sensitivity and 
accuracy (163). Nevertheless , it is frequently used as for validation of other instruments and 
generally shows good correlation with other physician reported instruments, albeit not with 
patient reported HRQoL (163). 
The Physician Global Assessment (PGA) is an instrument for assessing psoriasis disease 
severity. There is no standard PGA (164) and the PGA may be used to measure disease 
severity at given point in time (static) or as change over time (dynamic). There is no agreed 
formulation of the static PGA (s-PGA), but it generally measures disease severity on a four to 
seven point ordinal scale, ranging from “clear” to “very severe” (163). The s-PGA correlates 
well with other physician and patient reported instruments used to assess psoriasis (163). The 




Table 5 Static Physician Global Assessment version used in the SPC. 
S-PGA score Interpretation 
1 Clear 
2 Almost clear 
3 Mild 
4 Mild to moderate 
5 Moderate 
6 Severe 
7 Very severe 
When patients are treated for psoriasis, the underlying disease severity cannot be measured 
directly using an instrument such as PASI given that the score of the instrument is affected by 
treatment. Furthermore, in many studies clinical data are missing and therefore treatment 
(topicals, phototherapy, and systemic treatment) is used to infer disease severity (165). 
Hospitalization with psoriasis as a main diagnosis has also been used as an indicator of severe 
disease; e.g. in Ahlehoff et al (2011) (117). The construct underlying this concept is that 
psoriasis treatment corresponds to the severity of the disease. A patient with mild disease can 
manage the disease without prescriptions or with topicals only; if the disease is moderate, 
phototherapy will suffice, and if the disease is severe, systemic treatment or hospitalization 
are needed to control the disease. This concept assumes that patients are managed optimally, 
which is not always the case (166). Nevertheless, it has been shown that treatment with 
topicals and systemics are valid markers for disease severity in psoriasis; with sensitivity and 
positive predictive values consistent with commonly accepted thresholds for observational 
research (165). 
4.4.2 Health related quality of life 
The impact of the disease on HRQoL is also a central outcome in psoriasis and has been 
measured using psoriasis specific, skin specific, and generic HRQoL instruments (167). In 
clinical trials, the DLQI is the most frequently used HRQoL instrument (167). The DLQI 
consists of ten domains, nine of them have four alternatives (“Not at all” to “Very much”) 
(159). The tenth domain pertains to impact of skin on work and studying and is rated as a 
dichotomous domain; with affirmative answers directed to a question with three levels (“Not 
at all” to “A lot”) (159). Eight domains may also be marked as non-relevant (159). The total 
score ranges from zero to thirty (159). Total DLQI score may be collapsed into five 




Table 6 DLQI categories. 
Total score Effect on patient’s life 
0 – 1  None  
2 – 5  Small  
6 – 10  Moderate  
11 – 20  Very large  
21 – 30  Extremely large 
Note: Adapted from Hongbo et al (2005) (168). 
4.4.3 Psoriatic arthritis 
In PSOREST PsA was defined by a registered diagnosis of the disease and in DermaReg, 
patients classified as having PsA had been diagnosed by a rheumatologist. In SPC, at 
inclusion, the study dermatologist assessed each patient for PsA by taking a medical history 
and asking for joint or back pain. If the dermatologists reported joint pain, the patient was 
seen by a rheumatologist and diagnosed according to the criteria presented in Moll and 
Wright (1973) (169). At the ten year follow-up, relevant patients were also assessed by a 
rheumatologist according to the Classification for psoriatic arthritis (CASPAR) criteria (170), 
the current gold standard for classification of PsA. The CASPAR criteria were not developed 
when SPC was initiated. For statistical analysis, the CASPAR was applied retrospectively for 
validation of the diagnosis of PsA. The CASPAR criteria include a radiological assessment 
but x-rays were not available in the SPC. Nevertheless, patients still needed three points on 
the CASPAR to be classified as having PsA. Not all relevant patients saw the rheumatologist 
and in some patients the rheumatologist could not make a conclusive diagnosis. In those 
patients, the dermatologist assessment, medical records, and register data were used to 
determine PsA status. 
4.4.4 Attrition and loss to follow-up 
To explore the potential impact of loss-to-follow up in Study 1, we compared baseline 
characteristics between patients who participated in the ten-year clinical examination and 
those who did not, stratified by onset phenotype. We also compared uptake of topical 
psoriasis treatment in the two groups. Treatment with topical medication for psoriasis was 
defined as a dispensed prescription of the following medications within one year of the ten 
year clinical examination: topical tars (ATC Code: D05AA), antracen derivaties (D05AC), 
other antipsoriatics for topical use (D05AX), topical corticosteroids (D07), and emollients 
(D02). Patients who died during follow-up were excluded from these analyses. 
4.4.5 Cause-specific mortality 
When relevant for assessment, all-cause mortality is the most unbiased end-point in clinical 
research (171). Cause-specific mortality allows for identification of the conditions resulting in 
death and provides a metric on the comorbidity burden in a patient population. For the study 
on cause-specific mortality, we identified the 15 leading causes of death according in the US 
CDC (172) and collapsed those into eight groups and four additional categories (suicide, 
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accidents, missing causes of death, and all other causes). The resulting categories along with 
ICD-10 diagnosis codes are presented in Table 7. 
Table 7 ICD-10 codes for the causes of death groups. 
Cause of death ICD codes 
Cardiovascular disease I00–I09, I11-I13, I15, I20–I51, I60–I69, I10, G45, G46, F01 
Neoplasms C00–C97, D00-D47 
Diabetes E10–E14 
Chronic lower respiratory disease J40–J47 
Neurological disease F00, F02, F03, G00-G44, G47 
Kidney disease N00–N19, N25–N37 
Infection A00-A99, B00-B14, B20-B99, J09–J18 
Liver disease B15-B19, K70-K77 
Suicide U03, X60–X84, Y87.0 
Accidents V01–X59, Y85–Y86 
Other causes Residual (excluding missing causes of death) 
4.4.6 Resources and costs 
In society, resources are scare and demand for resources needs to be prioritized. This is also 
true for the health care sector: Available health care resources are insufficient to address all 
health needs and we have to decide which health needs to prioritize. This scarcity underlies a 
key concept in economics: The opportunity cost (173). The opportunity cost is the highest 
benefit foregone by committing a resource to a specific good or service. In other words, the 
opportunity cost of a specific resource is the benefit that would have been derived from the 
best alternative use of that resource. This concept of costs differs from financial costs: the 
price of goods and services. In theory, in a perfect market, the unit cost (price) for a product 
or service should equate opportunity costs (173). In practice, markets are imperfect but unit 
costs are used to approximate the opportunity cost (173). 
In economics, the concept of costs may be extended beyond goods and services and in health 
economics, three cost categories are frequently used: Direct, indirect, and intangible costs 
(174). Direct costs reflect healthcare services and goods; indirect costs reflect to lost 
production; and intangible costs reflect lost health (174). 
Another important aspect of costs is the perspective (175). For example, from the perspective 
of a patient covered by a health insurance, the costs for an operation may be limited to the co-
payment. On the other hand, from the insurer perspective, the cost may include not only the 
operation, but also rehabilitation. 
Whilst, costs are difficult to measure and depend on perspective, they are integral to decision-
making as they inform choices we have to make (173). Costs can also be informative in other 
ways as they can describe and contextualize the burden of a disease (176). For example, it has 
been argued that knowledge of the costs of a disease in a population provides important 
information to decision makers on research funding (176). Arguably, for society as a whole, 
diseases with higher burden merit more attention than diseases with lower burden. 
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In this thesis, direct costs were estimated for outpatient care, inpatient care, and prescriptions 
dispensed from pharmacy. Outpatient care costs were estimated by applying unit costs 
obtained from public payers to outpatient healthcare contacts; costs for inpatient care were 
derived using Diagnoses Related Group (DRG) points and a cost per DRG point; and costs 
for medication were estimated using the cost to the patient and payer combined, obtained 
from the PDR. Indirect costs were estimated using the human capital approach: The observed 
number of days on sick leave, activity compensation, and sickness compensation were costed 
at the mean daily gross salary (including employer’s contribution) in Sweden.  
Given that psoriasis is associated with comorbidities, estimating costs for psoriasis related 
resource use only would underestimate the costs of the disease. Comparing costs between 
patients with and without psoriasis may provide a more accurate reflection of the cost burden 
of the disease. Therefore, the costs of psoriasis in this thesis were estimated as the difference 
between patients with psoriasis and age- sex-, and residency matched controls. 
4.4.7 Treatment events 
Drug survival and persistence are two terms for the same concept: The length of time from 
initiation to discontinuation of therapy. In chronic symptomatic disease drug survival is a 
proxy for successful treatment (177). The underlying notion is that treatment discontinuation 
results from lack of effectiveness, adverse events, or treatment dissatisfaction. Therefore, 
longer treatment duration should be associated with better outcomes. 
Drug survival is a frequently studied outcome (127), but it is a crude proxy and arguably 
other treatment events such as dose titration above the label dose, and initiation of 
augmentation treatment should be added to drug survival to better measure effectiveness. 
Furthermore, to the extent data on signs and symptoms of the disease are available, these 
would also give important information on the effectiveness of treatment, and end-points 
combining drug survival and HRQoL have been explored in psoriasis (178). 
Switching is linked to drug survival in the sense that patients who switch treatment will 
discontinue the original treatment. However, the timing of the switch may reflect the reason 
for treatment discontinuation: If a treatment switch occurs in close proximity to the treatment 
discontinuation it is arguably more likely that the original treatment was discontinued due to 
lack of effectiveness or side effects. 
Time from treatment discontinuation to start of new therapy may also be a proxy of unmet 
need: A short duration between treatment discontinuation and start of a subsequent treatment 
may indicate that the original treatment was not sufficient or that the disease flared rapidly 




4.5 STATISTICAL METHODOLOGY 
4.5.1 Descriptive statistics 
In general, numerical variables that had an approximately normal distribution were described 
using mean and standard deviation (SD); numerical variables with another distribution were 
described using median and percentiles (e.g. interquartile range [IQR]); and categorical 
variables were reported using frequencies and percentages.  
4.5.2 Univariable analysis 
When data could be assumed to be IID and the patient count was sufficiently high, 
comparisons of means between groups were conducted using t-tests (179) by virtue of the 
CLT (180). However, in analyses on costs involving groups with fewer than 1,000 subjects, 
p-values were derived using the bootstrap methods (181).  
For categorical variables, comparisons between groups were conducted using chi-square tests 
(182) or McNemar’s test (183) as applicable. Confidence intervals for proportions were 
derived using the exact method (184). 
For time-to-event analysis, we used the Kaplan-Meier product limit estimator (185) to 
estimate the proportion of patients who had experienced (or had not experienced) an event at 
a given observation time.  
Relative risks of a dichotomous outcome given a covariate were derived using binomial 
generalized linear models (GLM) with a log-link (186). 
Locally weighted regression (LOESS) is a non-parametric regression model (187). LOESS 
was used to fit smooth curves of PASI and DLQI by treatment and years since treatment 
initiation. 
4.5.3 Multivariable analysis 
The form of regression model was chosen by selecting models with appropriate family and 
link functions: Binomial family and logistic link (logistic regression) for binary outcomes; 
gamma family and identity link for costs; and Gaussian family and identity link (linear 
regression) for DLQI and PASI. For time-to-event data, Cox proportional hazard models 
(PH) (188) were fit and the PH assumption tested using at least one of three methods: visual 
inspection of LOESS curves for Schoenfeld residuals, visual inspection of log(–log) plot of 
the survival distribution functions, or inclusion of interactions between observation time and 
covariates in the models. (189) The PH assumption was valid unless otherwise noted. 
In Study 1, Firth type penalization (190) was implemented to reduce sparse data bias (191) in 
Cox PH and logistic regression when there were fewer than ten events per covariate. 
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4.5.4 Marginal effects estimation 
In Study 5, we estimated the marginal effect of each treatment (192). The marginal effect of a 
treatment is the average outcome expected if all patients had received that treatment (192). 
The marginal effects were estimated using the predictions from the multivariable regression 
models. 
4.5.5 Multilevel analysis 
For univariable and multivariable analysis, when the same patients had multiple observations 
in the same model, data were not considered IID and therefore random intercept regression 
models (193) were fit. Linear regression was implemented for continuous outcomes; logistic 
regression for binomial outcomes, ordinal logistic regression for ordered categorical 
outcomes with more than two levels; and shared frailty models for time-to-event data (193). 
4.5.6 Covariate selection  
The objectives of regression modelling can be descriptive, predictive or exploratory (194). In 
this thesis, the regression models were mainly fit for explanatory purposes. Therefore, we 
included covariates that could be assumed to be causally related to both the main covariate of 
interest and the outcome. In Study 1, the multivariable models were more descriptive in 
nature and predominately fitted to complement the recursive partitioning analysis. In Studies 
2 and 3, the variable selection was conducted informally. In Study 5, variable selection was 
formalized using Directed Acyclic Graphs (DAGs) (195).  
4.5.7 Recursive partitioning  
Recursive partitioning was implemented using a conditional inference framework with 
adjustments for multiple testing (196). Variables that have previously been associated with 
the outcomes were included in the recursive portioning analysis. The apparent discriminative 
ability of models was estimated using c-indices (197, 198) excluding ties on predictor groups 
(199). 
4.5.8 Bootstrapping 
Health care cost data may be heavily skewed with many observations at zero and few 
observations with very high values (200). Therefore, the CLT may not be applicable for 
modest sample sizes and we implemented bootstrapping to perform inferential tests and 
derive confidence intervals for strata with fewer than 1,000 patients, as recommended by 
Desgagné et al (201). P-values were derived using the bootstrap t-statistic and the bias 
corrected percentile method (181) was implemented to derive 95% confidence intervals. 
4.5.9 Sensitivity analysis of unmeasured confounders 
We explored the potential impact of unmeasured confounders in Study 2 using the approach 
described in Lin et al (1998) (202). We estimated the relative risks of an unobserved risk 
factor required to nullify the observed associations given assumptions on prevalence of the 
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unobserved risk factor in the two groups. We performed this analysis both for the point 
estimate and for the lower bound of the 95% CI. 
4.6 ETHICAL CONSIDERATIONS 
All studies obtained ethics approval (DNR: 00-448 for SPC, DNR 20101954-315 for 
PSOREST, and DNR 2018-1080-31 for DermaReg) and each registry holder also approved 
the study. Hence, the study design, conduct, and plan fulfilled formal ethical requirements. 
A common approach to consider ethical matters in biomedical research is grounded in four 
core principles: beneficence (doing good), non-maleficence (avoiding harm), autonomy, and 
justice (203). The discussion below focuses on the four principles in the context of the three 
studies presented in the five constituent papers. 
For all studies, one source of beneficence is the knowledge generated by the research. In 
addition, the SPC and DermaReg-Pso may have benefitted study participants directly. The 
SPC included a survey, a clinical examination and laboratory analyses. Findings from these 
may have been used to optimize treatment of psoriasis, or refer study participants to other 
health care providers as necessary. DermaReg-Pso includes a visualization tool and is used by 
clinicians and patients to follow disease activity, treatment, and outcomes over time, 
informing clinical decision-making, thereby benefitting study participants directly. PSOREST 
is based on secondary data and there were no direct benefits to the participants in the study.  
The most direct potential maleficence for the three studies is integrity breach. To address this 
harm, data were pseudonymized and stored safely with access only to relevant members of 
the study team in accordance with laws and regulations. Furthermore, no patient identifiable 
data were published. Another potential harm from the studies is that patients may feel 
discomfort or distress from the findings. For example, knowing that one’s risk of death may 
be elevated compared to the general population can be disquieting. Therefore, care needs to 
be taken when communicating the data to patients. Furthermore, it may be argued that the 
questions asked in SPC and DermaReg could cause distress for patients. In SPC, this 
challenge was addressed by consulting three patients in the development of the CRFs. In 
SPC, a blood sample was collected from participants, resulting in physical discomfort and 
risk of infection. The blood was drawn by trained professionals in a hospital setting using 
best practices, minimizing discomfort and other risks. 
In the SPC and DermaReg, participants provided informed consent that may be withdrawn at 
any time, arguably fulfilling the principle of autonomy. However, no informed consent was 
obtained in PSOREST, as this type of research do not require informed consent, partially to 
avoid identification of participants. However, the vast majority of individuals in Sweden 
support the use of their medical data for research purposes (204) , and it could be argued that 
data generated from health care consumption belongs to the entity that finances the health 
care, i.e. the tax payers as a collective.  
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In SPC and DermaReg, it appears that the probability of benefits and harms of the study are 
equally distributed among study participants and that the principle of justice is therefore 
fulfilled. For PSOREST, potential benefits of the study would likely accrue disproportionally 
in patients with psoriasis relative to the control population. However, the control population 
may still benefit from improved resource allocation that may result from the study findings. 
Following from the discussion above, I consider that potential benefits with the studies 
outweigh potential harms and that problems with autonomy and justice are limited. 







5.1 CLINICAL COURSE OF PSORIASIS (STUDY 1) 
5.1.1 Cohort and patients characteristics 
In the SPC, 721 patients were enrolled and eligible for analysis. After ten years, 546 of 686 
patients alive completed a questionnaire and 509 (74%) were examined clinically. On 
average patients were examined six months after disease onset (Median 6 months, IQR: 3-10 
months) and the median time from enrollment to the follow-up examination was 9.6 years 
(IQR: 8.8-10.4). 
At onset 542 (75%) had plaque phenotype, 174 (24%) had guttate phenotype, and five (1%) 
had other phenotypes. 
5.1.2 Disease course 
At the ten year clinical examination, 346 of 389 patients with plaque onset (89%) retained 
plaque phenotype, 13/389 (3%) had non-plaque phenotype, and 30/389 (8%) were in 
complete remission. In patients with guttate phenotype at onset, 75/116 (65%) had developed 
plaque psoriasis, 4/116 (3%) had non-plaque phenotype, and 37 (32%) were in complete 
remission. 
Figure 4A and Figure 4B present the distribution of disease severity at enrollment (mild, 
moderate, and severe) and ten-year clinical examination (minimal disease activity, mild, 
moderate, and severe), along with transitions between strata. Patients with severe plaque 
psoriasis at onset were more likely than patients with mild or moderate plaque psoriasis to 
have severe psoriasis at ten years (11/27 [41%] vs 34/362 [9%]; RR=4.3; p<0.001). Similarly, 
patients with mild plaque psoriasis at onset were more likely than patients with moderate or 
severe psoriasis to have minimal disease activity at the ten years (59/253 [23%] vs 18/136 
[13%]; RR=1.8; p<0.001). A minority of patients with severe guttate psoriasis at onset had 
severe psoriasis at ten years (4/22 [18%]), albeit a higher proportion than among those with 
mild or moderate guttate psoriasis at onset (1/94 [1%]). 
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Figure 4 Phenotype and disease severity from onset to ten years. Panels A and B show the distriubtion of disease 
severity at onset and ten years in patients with plaque onset (Panel A) and guttate onset (Panel B). Minimal disease 
activity was defined as a PASI below one without treatment. Mild disease was defined as topical therapy or PASI 
between one and five, moderate disease was defined as treatment with phototherapy or PASI between five and ten, and 
severe disease was defined as PASI exceeding ten or treatment with systemics.  
5.1.3 Psoriatic arthritis 
In patients with plaque phenotype at onset, the proportion of patients with PsA grew from 
69/389 (18%) at enrolment to 102/389 (26%) at ten years (p<0.001). In patients, with guttate 
phenotype at onset, the proportion of patients with PsA grew from 5/116 (4%) to 16/116 
(14%) (p=0.02). 
5.1.4 Subgroups and prognostic factors 
We identified subgroups with distinctive risks for developing severe psoriasis, clinical 
remission, and PsA (Figure 5). Regarding development of severe disease, patients with non-
guttate phenotype whose s-PGA exceeded 3 (mild disease) and had scalp lesions, had the 
highest cumulative incidence of severe psoriasis 52% (95% CI: 41% to 64%) over 12 years 
compared to 11% (95% CI: 8% to 14%) in patients with s-PGA at three or less. The 
probability of clinical remission was 57/116 (49%) in patients with guttate onset psoriasis, 
59/177 (33%) in patients with non-guttate psoriasis who were also free from scalp lesions; 
and 23/216 (11%) in patients with non-guttate onset and scalp lesions. The risk of PsA at ten 
years was highest among patients with peripheral enthesitis at enrollment 48/82 (59%), 
compared to 24/97 (25%) in patients with arthralgia but no enthesitis, and 37/304 (12%) in 
patients without arthralgia. The RPA derived algorithm for severe disease and mild disease 










Figure 5 Classification trees and outcomes for the identified groups for severe psoriasis, minimal disease 
activity at ten years, and psoriatic arthritis. Each node in the classification trees shows the identified splitting 
factor along with respective outcome: Cumulative incidence of severe psoriasis over 12 years (Panel A); proportions 
of patients with minimal disease activity at ten years (Panel B); and proportion of patients with Psoriatic Arthritis 
(PsA) at ten years (Panel C). Panel D (cumulative incidence of severe disease), Panel E (proportion of patients with 
minimal disease activity at ten years), and Panel F (proportion of patients with PsA at ten years) show outcomes in 
the groups identified in the recursive partitioning. Please note that in Panel A, two leaf nodes were combined (into 
Group 2) given that the outcomes in the two node groups were not significantly different; furthermore, 26 patients in 
Cohort B did not have data on peripheral enthesitis and therefore the number of patients in the classification tree for 
PsA was 483 (Panel E). Note: Cum. Inc. in panel A stands for cumulative incidence; CI stands for confidence 
interval; PsA stands for Psoriatic Arthritis.  
In addition to the characteristics identified as predictors of severity in the RPA, a number of 
variables were associated with disease severity. In patients with plaque onset, smoking 
increased the risk for developing severe disease (HR: 1.70; 95% CI: 1.10 to 2.63) and 
reduced the probability of achieving minimal disease activity at ten years (OR: 0.41; 95% CI: 
0.22 to 0.77). Similarly, male sex was significantly associated with both severe disease 
(increased risk) and clinical remission at ten years (reduced probability) in univariate 
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analyses. Furthermore, in multivariate analyses, PsA was significantly associated with severe 
disease and infection triggered disease was significantly associated with clinical remission at 
ten years. 
5.1.5 Attrition bias 
There were no marked differences in baseline characteristics between participants and non-
participants in the ten year clinical examination irrespective of phenotype at onset (Table 8 




Table 8 Comparison of baseline characteristics in patients with plaque onset who participated in the ten year 
clinical examination versus patients with plaque onset who were lost to follow-up. 
Characteristic CC LF p-value 
Age – yr median [range] 42 [30-55] 47 [26-59] 0.144 
Female sex - no. (%) 209/389 (54) 68/121 (56) 0.634 
BMI – mean (SD) 25.4 (4.4) 24.7 (4.5) 0.097 
Smoking - no. (%) 144/389 (37) 39/116 (34) 0.504 
Comorbidity profile - no. (%)     
Diabetes  13/389 (3) 5/121 (3) 0.681 
Hypercholesterolemia 101/389 (26) 29/121 (24) 0.660 
Hypertension 123/389 (32) 51/121 (42) 0.033 
Obesity 52/389 (13) 14/121 (12) 0.607 
Depression 15/389 (4) 7/121 (6) 0.362 
Potential precipitating factors - no. (%)    
Infection 52/389 (13) 21/121 (17) 0.274 
Life crisis 191/389 (49) 52/121 (43) 0.239 
Genetic weight - no. (%)    
First degree 124/389 (32) 48/121 (40) 
0.281 Second degree 59/389 (15) 17/121 (14) 
Higher degree, none, or unknown 206/389 (53) 56/121 (46) 
Disease severity    
PASI – median [range] 2.8 [1.5-4.5] 2.9 [1.4-4.9] 0.780 
s-PGA – median [range] 3 [2-4] 3 [2-4] 0.571 
Joint problems - no. (%)    
Self-reported joint pain 172/389 (44) 50/121 (41) 0.575 
Peripheral enthesitis 73/370 (20) 17/116 (15) 0.220 
Note: CC – Complete Cases; LF – Lost to Follow-up; PASI – Psoriasis Area and Severity Index; BMI – Body Mass Index; s-PGA – Static 




Table 9 Comparison of baseline characteristics in patients with plaque onset who participated in the ten year 
clinical examination versus patients with guttate onset who were lost to follow-up. 
Characteristic CC LF p-value 
Age – yr median [range] 32.5 [23-41] 28 [20-38] 0.302 
Female sex - no. (%) 73/116 (63) 33/55 (60) 0.712 
BMI – mean (SD) 24.4 (4.8) 23.3 (3.7) 0.129 
Smoking - no. (%) 45/115 (39) 17/53 (32) 0.379 
Comorbidity profile - no. (%)        
Diabetes  1/116 (1) 1/55 (2) 0.587 
Hypercholesterolemia 12/116 (10) 6/55 (11) 0.911 
Hypertension 18/116 (16) 7/55 (13) 0.630 
Obesity 9/116 (8) 2/55 (4) 0.305 
Depression 3/116 (3) 2/55 (4) 0.703 
Potential precipitating factors- no. (%)       
Infection 90/116 (78) 35/55 (64) 0.055 
Life crisis 34/116 (29) 22/55 (40) 0.164 
Genetic weight - no. (%)    
First degree 40 (34) 24 (44) 
0.312 Second degree 13 (11) 8 (15) 
Higher degree, none, or unknown 63 (54) 23 (42) 
Disease severity       
PASI – median [range] 4.1 [2.6-7.3] 4.1 [2.9-5.2] 0.106 
s-PGA – median [range] 3.5 [3-4] 3 [3-4] 0.216 
Joint problems - no. (%)       
Self-reported joint pain 31/116 (27) 16/55 (29) 0.746 
Peripheral enthesitis 8/109 (7) 8/54 (15) 0.131 
Note: CC – Complete Cases; LF – Lost to Follow-up; PASI – Psoriasis Area and Severity Index; BMI – Body Mass Index; s-PGA – Static 




There was no statistically significant difference in topical treatment the year before the 
clinical examination in patients who participated in the follow up compared to those who did 
not (41% vs 35%; p=0.145, Figure 6). 
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5.1.6 Impact of early systemic treatment 
Among the 66 patients who started systemic treatment before the clinical examination at ten 
years, patients who initiated treatment at or before the enrolment examination had lower 
probability of severe disease at ten years compared to patients who started systemics 
subsequently (6/16) [38%] vs 33/50 [65%]) (p=0.044) (Figure 7). After adjustment for 
factors associated with development of severe disease (s-PGA, smoking, PsA, and scalp 
psoriasis) early systemic intervention was still associated with decreased risk of severe 
disease at ten years (OR: 0.24; 95% CI: 0.06 to 0.90). 
 
Figure 7 Proportion of patients with severe psoriasis at the 10-year clinical examination stratified by time to 
systemic initiation. The figure shows the proportion of patients with severe disease at the ten year clinical 
examination and exact binomial 95% confidence limits among patients ever treated with systemics for psoriasis 
stratified by time to systemic initiation: At or before study enrolment, and during first, second, or third tertile of 
follow-up. 
5.2 CAUSE-SPECIFIC MORTALITY (STUDY 2) 
There were no statistically significant differences in mean age or sex distribution between the 
patient and control cohorts, reflecting the study design. However, mean CCI was higher in 
patients than controls: 0.26 in patients with mild disease vs 0.21 in their controls (p<0.001) 
and 0.36 in patients with severe disease vs 0.25 in their controls (p<0.001).  
The estimated number of excess deaths per 1,000 person years was 1.77 in patients with mild 
disease and 6.76 in patients with severe disease. Among subjects who died, patients with mild 
psoriasis were on average 0.8 years younger and patients with severe psoriasis 2.6 years 
younger than corresponding controls. Cardiovascular disease was the most common cause of 
death in both patients and controls. The proportion of excess all-cause mortality attributable 
to cardiovascular disease was 48% in patients with mild psoriasis and 33% in patients with 
severe psoriasis. 
The estimated HRs and 95% CIs for all-cause and cause-specific mortality after adjusting for 
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severe psoriasis for all-cause mortality were estimated at 1.15 (95% CI: 1.10 to 1.21), and 
1.56 (95% CI: 1.36 to 1.79), respectively. For patients with mild disease, the causes of death 
with the highest excess point estimates were kidney disease (HR: 2.20, 95% CI: 1.36 to 3.56), 
and liver disease (HR: 2.00; 95% CI: 1.34 to 2.99). For patients with severe disease, the 
highest HR point estimates were observed for liver disease 4.26 (95% CI: 1.87 to 9.73), and 
missing causes of death 3.42 (95% CI: 1.24 to 9.44). The risk of death from neurological 
disease was statistically significantly lower in patients with mild disease than controls (HR: 
0.64; 95% CI: 0.50 to 0.83) and similar in patients with severe disease compared with 
controls (HR: 0.51; 95% CI: 0.21 to 1.23).  
Figure 8 Estimated hazard ratios for specific causes of death and all-cause mortality among patients with mild 
and severe psoriasis compared with controls controlling for comorbidities. 
5.3 ECONOMIC BURDEN (STUDY 3) 
Reflecting the matched study design, differences in sex and age between patients and controls 
were small. However, comorbidity burden measured using CCI was higher in all severity 
strata (p<0.01). 
Patients had higher total HCRU costs than controls after adjusting for CCI: USD 3,555 versus 
USD 2,190 (p<0.001). The mean difference in total HCRU costs (USD) adjusted for CCI 
between patients stratified by most potent treatment class (none, topical, phototherapy, 
systemic, biologic, and hospitalization) and controls were estimated at 326 (95% CI: 243 to 
409), 1,203 (95% CI: 1,031 to 1,375), 2,816 (95% CI: 2,222 to 3,410), 1,845 (95% CI: 1,422 
to 2,269), 17,246 (95% CI: 16,416 to 18,076), and 16,947 (95% CI: 13,813 to 20,082), 
respectively. 
Patients also had higher indirect costs than controls after adjusting for the CCI: USD 9,898 
versus USD 6,579 (p < 0.001). The difference in mean total indirect costs (USD) adjusted for 
the CCI between patients stratified by most potent treatment class (none, topical, 
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phototherapy, systemic, biologic, and hospitalization) and controls were estimated at 1,781 
(95% CI: 1,395 to 2,168), 3,697 (95% CI: 2,973 to 4,421), 1,844 (95% CI: 424 to 3,264), 
4,523 (95% CI: 2,912 to 6,133), 7,874 (95% CI: 5,482 to 10,265), and 18,935 (95% CI: 2,494 
to 35,376), respectively. 
Among the 121 patients persistent with biologic treatment for at least 12 months, mean costs 
of the biologics during the 12 months period were estimated at USD 23,293 (95% CI 22,372 
to 24,199). To estimate potential cost offsets with biologics, three counterfactual scenarios on 
the cost development in the absence of biologic initiation were explored. The first scenario 
was that costs would been the same as the 12 month period prior to treatment initiation. The 
second scenario was that costs would have been constant at the level observed the 
penultimate month before treatment start. The third scenario was that costs would have been 
constant at the level observed the final month before treatment start. In the first scenario the 
12 months direct and indirect costs offsets were estimated at USD 1,135 (95% CI 328 to 
2,050) and 774 (95% CI: -535 to 2,019), respectively. In the second scenario the direct and 
indirect costs offsets were estimated at USD 1,944 (95% CI: 587 to 3,749) and 1,875 (95% 
CI: 188 to 3,650), respectively. In the third scenario the direct and indirect cost offsets were 
estimated at USD 4,422 (95% CI: 2,771 to 6,552) and 1,794 (95% CI 537 to 3,377), 
respectively. 
5.4 TREATMENT PATTERNS (STUDY 4) 
The cumulative incidences of treatment discontinuation at one year with topicals, systemics, 
and biologics were estimated at 88%, 48%, and 43%, respectively (Figure 9, Panel A). The 
cumulative incidence of any treatment event (discontinuation, switch, or augmentation) at one 
year with topicals, systemics, and biologics were estimated at 93%, 72%, and 75%, 
respectively (Figure 9, Panel B). Over the observation period, the rate of treatment 
discontinuation was lower with biologics than systemics (p=0.044), whereas overall treatment 
event rate was higher with biologics than systemics (p=0.003). 
For biologics, the cumulative incidences of insufficient treatment results within twelve and 24 
months of treatment start were estimated at 29% and 41% respectively (Figure 9, Panel C). 
Within one year of having discontinued treatment, the cumulative incidence of starting a new 
treatment was 49% for topicals, 61% for systemics, and 80% biologics (Figure 9, Panel D). 
The proportion who restarted the same treatments they discounted was estimated at 53% for 





Figure 9 Kaplan Meier Product Limit Estimators Plots. Panel A presents estimated time to treatment 
discontinuation. Panel B presents estimated time to first treatment event (discontinuation, switch, and augmentation). 
Panel C presents estimated time to insufficient treatment result with biologics; and panel D presents estimated time to 






5.5 REAL-WORLD EFFECTIVENESS OF ADALIMUMAB, ETANERCEPT, AND 
METHOTREXATE (STUDY 5) 
In total, 727 treatment episodes with adalimumab, etanercept, and methotrexate in 524 
patients were analyzed. Mean age (SD) in the cohort was 48.3 (15.6) years, mean BMI was 
27.4 (5.1), 326 patients (62%) were male, 180 (34%) had PsA, and 159/516 (31%) smoked. 
The drug survival for ADA, ETN, and MTX are presented in Figure 10. In the unadjusted 
model, no statistically significant difference between ADA and MTX was found (HR: 0.80; 
95% CI: 0.62 to 1.04), whereas ETN had worse drug survival than MTX (HR: 1.56; 95% CI: 
1.25 to 1.95). In the analyses adjusted for covariates, ADA had higher drug survival than 
MTX (HR: 0.67; 95% CI: 0.51 to 0.88), whereas no statistically significant difference 
between ETN and MTX was found (HR 1.23; 95% CI: 0.97 to 1.56). 
Figure 11 presents LOESS plots of disease severity measured as PASI and DLQI during 
treatment with ADA, ETN and MTX. In regression models adjusting for confounders, ADA 
had lower mean PASI (-2.0; 95% CI: -2.6 to -1.5) and lower mean DLQI (-0.9; 95% CI: -1.5 
to -0.3) than patients on MTX during maintenance treatment. Using the same regression 
framework to compare ETN to MTX, ETN had lower mean PASI during maintenance 
treatment (-0.7; 95% CI: -1.2 to -0.2) whereas there was no statistically significant difference 
in mean DLQI between the treatments (- 0.5; 95% CI:  -1.1 to 0.1). 
In analysis of marginal mean PASI and DLQI, predicted mean PASI during maintenance 
treatment with ADA, ETN, and MTX were 2.9 (95% CI: 2.5 to 3.3), 4.2 (95% CI: 3.8 to 4.6), 
and 4.9 (95% CI: 4.6 to 5.3), respectively. The predicted mean DLQI with ADA, ETN, and 





Figure 10 Drug survival in patients with moderate to severe psoriasis. The figure shows time to treatment 
discontinuation with methotrexate, etanercept, and adalimumab in DermaReg.  
 
Figure 11 LOESS curves for PASI and DLQI. The figures present LOESS curves for PASI (Panel A) and DLQI 







6.1 METHODOLOGICAL CONSIDERATIONS  
6.1.1 Stockholm Psoriasis Cohort (Study 1) 
6.1.1.1 Selection bias 
The target population in the SPC was patients with incident psoriasis in Sweden. The target 
sample was patients fifteen years or older with first onset of psoriasis within the last twelve 
months on non-hairy skin. The actual sample was the 721 patients, predominately from the 
Stockholm area, Sweden, with first recalled onset of psoriasis within the last twelve months 
on non-hairy skin who enrolled in the study. Furthermore, sex-, age-, and postcode-matched 
controls were enrolled into the study. 
The SPC had a broad recruitment strategy to obtain a representative sample of patients with 
new onset psoriasis. However, the actual sample was not randomly selected and patients were 
required to provide informed consent, therefore the actual sample is likely systematically 
different from the target sample. In particular, patients with limited lesions and frail patients 
may be underrepresented in the study.  
The SPC was a long-term prospective observational study and is susceptible to attrition bias – 
a type of selection bias in which those who complete the study are systematically different 
from those who do not. Among the 686 patients alive at ten years, 546 (80%) completed a 
questionnaire and 509 (74%) were also examined clinically. Registry data allowed for 
virtually complete follow-up of all patients in terms of filled prescriptions, specialist 
outpatient visits, and inpatient care. A comparison of filled prescriptions for topicals used to 
treat psoriasis in patients who participated in the ten year clinical examination compared to 
those who did not, found that treatment uptake was similar between the two groups. Finally, 
baseline characteristics were similar between those who completed the study and those who 
did not. Taken together these data suggest that attrition bias should be limited. However, it is 
impossible to rule out the risk of attrition bias completely as full data were not observed for 
those who did not complete the study. 
6.1.1.2 Information bias: 
Two dermatologists specializing in psoriasis diagnosed all patients in the SPC at enrollment, 
minimizing misclassification of exposure. History of skin lesions were elicited from the 
patients and it is possible that some patients may have forgotten about prior lesions or failed 
to notice the lesions when they occurred. Therefore, some patients defined as having recent 
onset psoriasis may have had prevalent disease. Patients were enrolled within one year of 
disease onset. Therefore, recall bias for factors associated with disease onset may exist. 
Furthermore, the majority of patients were treated between onset and the enrollment, making 
direct assessment of underlying disease severity using instruments such as PASI or s-PGA 
challenging. For Study 1, the only information related to the onset elicited from patients were 
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stressful life events and infections requiring antibacterial or antiviral treatment; two types of 
events that should be easy to recall.  
The two main outcomes were skin disease severity and PsA. The true disease severity of skin 
psoriasis is confounded by treatment. Therefore, we defined disease severity as a composite 
end-point comprising PASI and treatment. The composite end-point is unlikely to be a perfect 
measure of actual disease severity. Furthermore, PASI was measured at up to three 
examinations and it is possible that some patients had severe disease that was not observed 
during clinical examination and was not treated with systemics. Some treatments for psoriasis 
may also be used in other indications, most notably PsA. To mitigate this potential 
misclassification bias, medical records were screened, and register data examined when 
medical records were inconclusive. 
Psoriatic arthritis may be susceptible to misclassification bias. It is a clinical diagnosis and the 
CASPAR criteria, developed for classification of PsA in patients in a rheumatology setting, 
may be less appropriate in a dermatology setting. In addition, one of the CASPAR criteria – 
juxtaarticular new bone formation on a radiograph – was not available in the SPC. However, 
in patients with inflammatory articular joint disease, current psoriasis and lack of rheumatoid 
factor are sufficient to classify patients as having PsA. At enrollment examination, all patients 
with inflammatory joint disease had current psoriasis lesions, and few were rheumatoid factor 
positive, indicating that radiographic data would have limited impact on the prevalence of 
PsA. At the ten year clinical examination, the PsA classification was also made using the 
CASPAR criteria and for patients in which the examination was inconclusive, medical 
records and registry data were consulted for classification. 
6.1.1.3 Confounding 
Study 1 was mainly descriptive in nature and multivariable regression was used to isolate 
potential predictors, rather than establish causality. However, the analysis of the impact of 
systemic treatment on disease severity at ten years was analytical and there may be residual 
confounding in the analysis. 
6.1.1.4 Statistical considerations. 
We evaluated the discriminatory power of the subgroups with differential risks for severe 
disease, minimal disease activity, and PsA using c-indices (197, 198). The c-indices were 
estimated based on the sample used to develop the algorithms and therefore likely 
overestimates the discriminative power of the subgroups (205). Internal validation using 




6.1.2 PSOREST (Studies 2, 3 and 4) 
6.1.2.1 Selection bias 
The target population in the PSOREST study was all individuals with psoriasis in Region 
Skåne and Västra Götaland. The target sample comprised all patients with diagnosed 
psoriasis between 2001 and 2010 in Region Skåne and between 2005 and 2010 in Västra 
Götaland. The actual sample comprised all patients with a registered diagnosis of psoriasis in 
the two regions during the relevant periods. The study also included sex-, age-, and residency 
matched controls without a diagnosis of psoriasis. 
One strength of PSOREST is the population based approach: All patients with a registered 
diagnosis of psoriasis in the Skåne and Västra Götaland regions within the relevant periods 
were included in the study. Therefore, the actual sample should be close to the target sample. 
Furthermore, healthcare in Sweden has universal access and is mainly funded with taxes. 
Patients are generally able to consume the health care they perceive they need and the target 
sample should be close to the target population. However, three caveats on patient selection 
should be noted. First, patients with psoriasis that did not come to clinical attention were not 
identified in the study. Second, visits to some private practitioners in Region Skåne did not 
have a diagnosis code (146). Third, we had a prevalent cohort design, only enrolling patients 
who survived and had a psoriasis diagnosis from 2001 in Region Skåne and from 2005 in 
Västra Götaland.  
Among the three limitations, the most problematic from a selection perspective is probably 
the exclusion of patients who have not sought clinical attention for their disease. It seems 
reasonable that the majority of individuals with psoriasis who do not have health care 
contacts have mild disease. Hence, the target sample may be biased towards severe patients. 
The underreporting of diagnoses from private practitioners in Region Skåne may also bias the 
sample towards severe patients, reflecting that patients treated exclusively in a primary care 
setting may have comparatively mild disease on average. 
The prevalent cohort design may be problematic in the study on cause-specific mortality. If 
patients with incident disease have a spike in mortality, we would not capture that spike as 
some of the most vulnerable patients would have died before study start. However, psoriasis 
is hypothesized to be associated with cumulative inflammatory burden (206), arguably 
resulting in increased relative risk of mortality with disease duration. A related source of 
selection bias is that that severely ill patients may not get a diagnosis of psoriasis even though 
they have the disease, biasing the psoriasis cohort to a comparatively healthy population, at 
least close to first registered diagnosis. 
For Study 4, treatment is the exposure of interest. Medications administered at a clinic may 
be obtained directly by the hospital and therefore not be registered in the PDR (150). This 
selection bias should be limited as 98-99% of ETN and ADA doses are channeled to 
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pharmacies (207). It is unlikely that other subcutaneous injections, orals, or topicals would be 
handled differently. 
6.1.2.2 Information bias: Measurement error in exposure 
The main source of misclassification bias for patient selection in PSOREST is that all patients 
in the study were not diagnosed by dermatologists, the gold-standard for a psoriasis diagnosis 
(5). However, primary care physicians have a diagnostic accuracy of 80% for typical and 
atypical psoriasis (6). Given that most patients by definition are typical, diagnostic accuracy 
should be higher on average. Furthermore, the SHCR has good positive predictive value for a 
psoriasis diagnosis with EMRs used as gold-standard (208). Misclassification of psoriasis is 
likely to be limited and mainly affect patients with mild disease. 
The problem of misclassification of patients with psoriasis as controls is likely limited 
reflecting that controls are sampled from the general population, and misclassified patients 
with psoriasis would be included pro rata from the general population. 
In Study 4, the exposure is treatment. The PDR does not have a structured variable (e.g. ICD-
10 code) for the indication of the prescription (150) and the relevant medications may have 
been used for other indications. This potential bias is likely largest for topicals, as we did not 
implement any restrictions and therefore some patients may have used the treatments for 
other indications. For traditional systemics and biologics, we implemented an algorithm 
based on diagnoses, clinic, and prescriber specialty. Even after application of the algorithm, 
misclassification may still exist. Theoretically, the algorithm should decrease sensitivity and 
increase specificity. To the extent outcomes are less variable within an indication than 
between indications, the algorithms should improve overall precision of the estimates. 
6.1.2.3 Information bias: Measurement error in outcome 
In terms of measurement error, a strength is that the data used for outcomes in Studies 2 to 4, 
i.e. filled prescribed drugs, procedure codes, health care contacts, and cause-specific mortality 
are available for practically all patients. However, a number of important limitations need to 
be noted in terms of outcome assessment. 
Study 4 considered four outcomes: persistence, any treatment event (composite of 
persistence, switch, and augmentation), treatment restart, and failure of biologic treatment. 
All outcomes were derived using prescriptions and procedure codes and contextual data are 
very limited. For example, the reason for treatment discontinuation is not noted. Therefore, 
patients who take a treatment holiday may be classified as having discontinued treatment. 
Furthermore, we do not know if patients actually consumed the filled prescriptions or not. In 
addition, not all relevant outcomes may be included. For example, treatment with infliximab 
or phototherapy that is not reimbursed would not be covered in the registers. The net effect on 
persistence from measurement error in outcome is difficult to assess: Treatment holidays may 
result in underestimation of persistence, whereas filled – but not consumed – prescriptions 
would overestimate persistence. Augmentation, switching, and failure of biologic treatment 
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may be biased downwards, reflecting missing outcome data on infliximab and home 
phototherapy. 
For Study 2, the outcome is cause-specific mortality. Virtually all deaths are captured in the 
CDR (152) but the identification of the underlying cause is a complex and partially subjective 
process. The quality of the causes of deaths in the CDR have not been systematically 
reviewed on deaths occurring later than 1995 (152). The misclassification between patients 
and controls is likely non-differential, biasing estimates toward the null. 
For Study 3, the outcomes were direct and indirect costs and a number of limitations should 
be noted. Firstly, it is uncertain whether the costs used in the analysis reflect the economic 
value of the products and services. Secondly, some relevant resource use may not have been 
captured, e.g. over the counter prescriptions and home-based phototherapy. Thirdly, we 
compared costs in individuals with and without psoriasis and some of the observed 
differences may not result from psoriasis or attributable comorbidities, but may reflect 
increased detection of comorbid diseases during health care contacts for psoriasis. In terms of 
indirect costs, the human capital approach was used to estimate the value of lost production 
and this method has been criticized for overestimating indirect costs (209). Another 
consideration for indirect costs is that most sick leave episodes shorter than 14 days are not 
recorded in MiDAS (156), potentially resulting in biased cost estimates: For example, a 
reduction of a sick leave episode by one day from 14 to 13 would be estimated as a reduction 
of 14 days. The net impact of measurement error in costs is difficult to assess. However, the 
estimated cost difference between patients with and without psoriasis is difficult to attribute 
directly to psoriasis. Using data from SHCR, Löfvendahl et al (2017) (136) found that 
psoriasis accounted for 7% of the difference in health care costs, 26% of the difference in 
drug costs, and 82% of the difference in indirect costs observed between patients with 
psoriasis and controls.  
6.1.2.4 Confounding 
The treatment patterns study was mainly descriptive whereas the studies on cause-specific 
mortality and economic burden were analytical. Therefore, confounding is a potential source 
of bias is the two latter studies. Two main limitations exist. Firstly, we did not use a formal 
framework to identify relevant confounders, such as DAGs. Secondly, we did not have 
information on possible confounders including obesity, smoking, excessive alcohol 
consumption, and exercise; factors that may be causally related to psoriasis, excess mortality, 
and increased health care consumption. 
The prevalent cohort design may also be problematic in terms of blocking of the causal 
pathway: psoriasis may impair health (for which CCI is a proxy in this study) and the CCI 
may therefore block the causal pathway from psoriasis to death. For example, psoriasis has 
been linked to myocardial infarction (32). Therefore, if a patient suffers a myocardial 
infarction causally linked to her psoriasis prior to study inclusion, adjusting for the CCI 
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(which includes myocardial infarction) would falsely attenuate the association between 
psoriasis and death.  
6.1.2.5 Statistical considerations. 
A number of statistical considerations should also be noted.  
In Study 4, the same patients were included multiple times in the same cohort, violating the 
assumption of independence between observations. Therefore, the confidence intervals 
presented in the analysis may not have the stated coverage and p-values may be erroneous.  
For Study 2, three limitations may be noted. The non-proportionality of the PH assumption 
may be problematic, but the impact should be limited given that the point estimates of HR in 
models starting one year into the follow-up were similar to the HRs in the base case models. 
Furthermore, given that we evaluated specific causes of death we censored patients who died 
from other causes. Whilst this assumption disregards competing risks, it is still valid when the 
objective is to evaluate whether a factor, such as a disease, is relevant from a biological 
perspective (210, 211). Finally, there were few deaths from some causes in the analysis of 
patients with severe disease, resulting in a potential spare data bias for certain outcomes, 
biasing the HR point estimate from the null (191). 
In the analysis of costs in Study 3, we fitted GLMs with an identify link. Therefore, the 
coefficients in the in the models are additive and it has been argued that costs should be 
modelled using a log-link instead (212) and, in theory, the identify link may produce 
predictions of costs below zero. However, the difference between identify link and log-link in 
GLM models of costs are minor in models with few covariates (213) and we chose the 
identify link for ease of interpretation. 
6.1.2.6 Transportability 
Transportability of the findings are uncertain. Firstly, the data come from two regions in 
Sweden and there may be significant variation in treatment within (214) and between 
countries (215). Secondly, the treatment armamentarium for moderate-to-severe psoriasis 
have expanded substantially in recent years and treatment goals have changed (216).Thirdly, 
the health care delivery and practice may differ between settings. Furthermore, relative 
measures have better transportability than absolute measures (217). Therefore, the findings on 
the impact of psoriasis on relative cause-specific mortality arguably have higher 
transportability than the findings on treatment patterns and economic burden; both which may 
be more difficult to extrapolate in time and space. 
6.1.3 DermaReg-Pso (Study 5) 
6.1.3.1 Selection bias 
The target population was all individuals treated with systemics for psoriasis in Region 
Stockholm. The target sample comprised all patients treated with systemics for psoriasis at 
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the Karolinska Sjukhuset and a treatment center in Sundbyberg, Stockholm run by the 
Swedish Psoriasis Association; and the actual sample comprised all patients registered in 
DermaReg-Pso at the two treatment centers. 
DermaReg-Pso enrolls patients from the two treatment centers with the highest volume of 
patients treated with systemics for psoriasis in Sweden. Whilst this may be considered a 
strength given that clinicians in these clinics should be experienced in diagnosis, treatment, 
and evaluation of psoriasis, it may systematically bias the target sample to more difficult 
patients. Furthermore, the register requires informed consent, and some patients opt out from 
the register, resulting in potential for systematic differences between the actual sample and 
the target sample. The impact of this potential bias is difficult to examine without data on the 
non-participating patients. 
6.1.3.2 Information bias 
There may be information bias in exposure, outcome and covariates. Firstly, the clinician 
reports treatment and it is not certain that patients take their medications; therefore, there may 
be misclassification in exposure. Secondly, effectiveness in psoriasis is a multi-faceted 
concept comprising clinical effectiveness, adverse events, HRQoL, and treatment 
satisfaction; and it is not certain that the end-points in the study adequately measure these 
constructs, resulting in potential misclassification of outcome. Thirdly, covariates may be 
measured with imprecision. For example, given the lack of washout prior to treatment 
initiation, disease severity prior to treatment initiation may not be an adequate marker for 
disease severity. Fourthly, bias may arise if follow-up differs systematically among the three 
treatments. We addressed the first two limitations by using multiple end-points: Treatment 
discontinuation arguably reflects treatment dissatisfaction, and drug survival, DLQI and PASI 
collectively captures broad aspects of psoriasis that are important to patients. We addressed 
the third limitation by evaluating disease severity over the entire period of data availability 
prior to initiation with the relevant treatment episode; and assessed the fourth limitation by 
examining the data and found no evidence of systematically differential follow-up among the 
three treatments. 
6.1.3.3 Confounding 
The study compared two treatments, adalimumab and etanercept to methotrexate, and the 
distribution of patient characteristics among the three treatments were uneven, suggesting 
potential confounding bias. We developed three DAGs to make underlying assumptions on 
causality explicit. It is possible that the DAGs are incorrect or omit important variables; and 
that residual confounding exists after controlling for variables as indicated in the DAGs. One 
example may be comorbidities such as inflammatory bowel disease for which ADA, and 




Differences in treatment targets, clinical practice, and patient selection may limit the 
transportability of the findings in space and time. Even within the study setting, changing 
treatment practice necessitated control for calendar year to address confounding. 
Furthermore, as evidenced by the analysis of PASI and DLQI during maintenance treatment, 
a number of patients had inadequately controlled psoriasis given current treatment targets and 
therefore drug survival estimates would likely differ in the current environment. Adherence to 
more strict treatment targets would reduce drug survival for all three treatments, but less for 
adalimumab than methotrexate.  
6.1.3.5 Statistical considerations. 
We fitted linear random intercept models with normally distributed errors and an identity 
link. PASI ranges between 0 and 72 and DLQI ranges between 0 and 30. During maintenance 
treatment, both PASI and DLQI are heavily skewed towards zero and it is possible that 





Psoriasis is a chronic inflammatory disorder affecting both body and psyche. The studies in 
this thesis aimed to expand our knowledge of its clinical course, comorbidities, economic 
impact, and treatment. 
Study 1 demonstrates that plaque psoriasis has a comparatively stable course. Patients with 
severe disease at onset were more than four times more likely to have severe disease after ten 
years than patients with mild or moderate disease (41% vs 9%; p<0.001). The study on 
treatment patterns also underscores the recalcitrance of psoriasis. A high proportion of 
patients restarted treatment within one year of discontinuation; with the probability increasing 
with potency of discontinued treatment: 49% for topicals, 61% for systemics, and 80% for 
biologics. The SPC also found that the course of psoriasis may be predicted with good 
discriminatory power. Patients with plaque phenotype, more than mild symptoms (s-PGA>3), 
and scalp involvement were more likely to develop severe psoriasis than patients with mild 
symptoms (s-PGA≤3), irrespective of phenotype at enrolment (52% vs 11%, p<0.001). For 
PsA, patients with peripheral enthesitis at enrollment were more likely to have PsA at ten 
years than patients who reported no arthralgia at onset (59% vs 12%, p<0.001). Therefore, 
patients with these characteristics at onset may merit comparatively close follow-up or 
referral to specialists; especially since undertreatment of both psoriasis and PsA appear 
common (166). In general, patients with guttate onset had a good prognosis with 48% having 
minimal disease activity after ten years. Furthermore, only 1/94 (one per cent) of patients 
with guttate phenotype of mild or moderate disease severity at onset had severe psoriasis at 
ten years. 
In terms of treatment, Study 5 found that ADA was superior to MTX whereas the findings for 
ETN versus MTX were more mixed. In line with results from clinical trials, these results 
suggest that ADA is more effective than MTX for treating skin manifestations of psoriasis, 
and may be a good option as a first line systemic treatment; albeit more data, especially on 
safety and costs are needed. In addition, even though ADA was comparatively effective, 
mean PASI was estimated at 2.9 during maintenance, reasonably in line with current 
treatment goals (45). However, the notion that psoriasis treatments may be insufficient is 
supported by the findings from Study 4 where more than 70% of patients on systemic and 
biologics augmented, switched, or discontinued treatment within one year from treatment 
start. Finally Study 1 found that early systemic treatment associated with reduced risk of 
severe disease at ten years: Six of 16 patients (38%) who initiated systemic treatment at or 
before enrolment had severe disease at ten years compared to 33 of 50 patients (65%) who 
started systemic treatment later in the disease course (p=0.044), a finding that was statistically 
significant after controlling for covariates. Given the non-randomized nature of the analysis, 
this finding should be viewed with a very high degree of caution and new studies, preferably 




Study 2 found that all-cause mortality was increased in both mild and moderate to severe 
psoriasis. Whilst cardiovascular deaths accounted for most excess deaths, the highest relative 
risks of death for patients with mild psoriasis and severe psoriasis were kidney disease, and 
liver disease, respectively. The reasons for the elevated risks of deaths due to cardiovascular, 
kidney and liver disease are unclear. However, these organs are interdependent; and all three 
are adversely impacted by systemic inflammation, smoking, and excess alcohol consumption; 
factors also are associated with psoriasis (218-220). Liver disease and kidney disease are less 
frequent causes of death than cardiovascular disease and are therefore arguably less important 
to screen. However, liver and kidney function tests are recommended to monitor systemic 
treatment in psoriasis (221) and could potentially be used to identify patients with elevated 
risks for kidney and liver disease. 
The study on the economic burden with psoriasis support the notion that psoriasis is 
associated with substantial direct and indirect costs and that the economic burden generally 
increases with disease severity. The analysis also demonstrates that treatment with biologics 
have the potential to decrease both direct and indirect costs, with the net impact on direct 
costs depending on the cost of biologics. This finding could inform economic evaluation of 
treatments in psoriasis and therefore improve resource allocation in the health care system.  
Overall findings from these studies reinforce the notion that plaque psoriasis is a chronic 
disease associated with substantial burden both from clinical and economic perspectives. 
Identification of subgroups of patients with adverse disease course may contribute to better 
and more cost-effective management of the disease. The finding that early systemic 
intervention may affect the disease course may affect the treatment paradigm in psoriasis, but 




8 POINTS OF PERSPECTIVE 
This thesis attempts to enhance our knowledge of clinical, epidemiologic and economic 
aspects of psoriasis. Even though new knowledge has been gained, new questions have also 
arisen due to results and limitations. 
The estimated effectiveness of novel systemics in psoriasis systematically differs between 
clinical trials and clinical practice (222). The reasons for these differences are debated (223) 
and may include patient characteristics, adherence, and treatment setting. Understanding the 
reasons for these differences may facilitate improved treatment outcomes in clinical practice. 
To this end, a study linking DermaReg to Swedish Health Registers may be valuable given 
the depth and breadth of data such a study would have. Furthermore, the observation that 
early systemic intervention may be disease modifying should be tested in a clinical trial; and 
such a trial is currently under way (224). 
The studies in this thesis support a large body of evidence showing that some patients do not 
respond to or lose response to novel systemics. Identifying genotypes/other biomarkers or 
phenotypes with differential response rates to given treatments would enable clinicians to 
better tailor treatment to patients. Given the depth of the data in DermaReg, a study 
systematically exploring predictors of treatment response on these data may be valuable.  
In terms of comorbidities and cause-specific mortality, all studies following patients over 
time rely on prevalent cohorts, albeit at least one study has implemented a wash-out period 
(225). Therefore, survivorship bias is a potential problem, and one that the SPC largely is free 
from. Therefore, even though SPC is limited in size, it may provide important information on 
comorbidities. Furthermore, detailed data on patients and controls from onset may enable 
identification of subgroups or patients with especially elevated risk of comorbidities. 
The data in SPC may also be used to describe development of disease severity with disease 
duration and age, and disentangle the impact of the two factors. The study is also well 
equipped to examine the hypothesized existence of two types of psoriasis: One with early 
onset and adverse prognosis (Type 1), and one with later onset and better prognosis (Type 2). 
It could also beneficially be used to examine drivers of disease severity in comparatively mild 
population, not frequently seen in a dermatological setting. 
One important limitation with SPC is that patients were not seen frequently and therefore the 
description of the clinical course of psoriasis has important limitations. New technology and 
the growth of investment in dermatology since the advent of SPC may facilitate a larger study 
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